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ABSTRACT
Site-specific labeling using E coli biotin ligase (BirA) and its 15-amino acid "acceptor
peptide" (AP) has been applied to study the function of various cellular proteins. In order to extend the
capabilities of biotin ligase-based labeling, we engineered key elements of the labeling platform. First
we characterized a novel peptide substrate (called "yeast acceptor peptide" (yAP)) for yeast biotin
ligase (yBL) that had been evolved by phage display. Assays performed in vitro and on the yeast
surface showed that the yBL/yAP pair was orthogonal to the BirA/AP pair, allowing two-color labeling
of different proteins on cells with differently-colored probes. Second, to improve the kinetic efficiency
of yAP, we developed a novel selection scheme based on yeast display. Model selections demonstrated
up to 1000-fold enrichment, and three rounds of selection on a randomized peptide library were
performed.
Third, we attempted to improve the kinetic efficiency of BirA through evolution by in vitro
compartmentalization (IVC). Because the original IVC protocol based on bead-linked DNA had many
technical problems, we developed a novel bead-less IVC protocol. An enrichment factor of 25 was
obtained in a model selection. Due to the single-turnover nature of the selection, however, this scheme
was not able to enrich highly active catalysts over moderately active ones.
In separate work, we turned our attention to the streptavidin-biotin pair. Again using bead-less
IVC, we performed a selection for streptavidin mutants that could bind a ketone analog of biotin with
high affinity. Two rounds of selection were performed but characterization of enriched clones was not
completed.
Finally, we helped to discover a mutant ligase that could catalyze attachment of a fluorinated
aryl azide photocrosslinker to proteins fused to a 17-amino acid peptide tag. The aryl azide probe was
tested and shown to be accepted by a W37V mutant of E coli lipoic acid ligase (LplA).
Thesis Supervisor: Alice Y Ting
Title: Associate Professor of Chemistry
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Chapter 1: Introduction
Understanding the structure and function of cellular components such as proteins,
nucleic acids, and other biomolecules is the main goal of biochemistry. Powerful tools such as
crystallography or nuclear magnetic resonance have been developed to reveal the structure of
biomolecules. Investigating the function of biomolecules also requires various experimental
tools that would allow for quantitative and experimentally well-defined monitoring at the
molecular level of the spatial and/or temporal cellular processes'. Many experimental
strategies such as immuno-precipitation have been developed for this purpose. Among these
strategies, cellular fluorescence imaging techniques have provided novel and important
information (e.g. protein localization and interaction with other biomolecules) in cell biology,
where most of it would not be obtainable with any other biological techniques.
Key elements of these cellular imaging techniques are fluorescent proteins (FPs) or
reporter proteins such as p-lactamase, p-galactosidase, and luciferase, which can be genetically
introduced into proteins of interest and provide high spatial or temporal information of the
target cellular proteins2 . Although they have been successfully used in biological studies to
visualize, track, and quantify proteins in live cells, a consensus drawback of FPs has been their
large size (Green fluorescent protein has 238 amino acids), which can make it difficult to study
the innate structure and function of the protein of interest3 , 4; for example, Baens and
coworkers demonstrated that EGFP (Enhanced Green Fluorescent Protein) fusion proteins
inhibit Lys 63-and Lys 48-linked polyubiquitination .
Compared to FPs, small molecule probes, on the other hand, display a variety of
properties and functions such as small size, photoreactivity, stable fluorescence, and versatile
functional group handles for modification. These facets of small molecule probes can be
utilized to develop more sophisticated strategies to explore cellular proteins in a non-invasive
manner. For example, protein substrates derivatized with photocaging groups can be used to
temporally and spatially regulate protein activities6 . Site-specifically labeled photoaffinity
probes can offer detailed molecular information about protein-protein interactions. Tissues in a
live animal can be imaged by using magnetic resonance imaging or positron emission
tomography probes. Moreover, electron microscopy probes provide much higher resolution for
cellular spatial information after cell fixation. One critical requirement for developing these
applications, however, is to target small molecule probes to specific proteins in the cellular
context. In the first part of this introductory chapter, current protein labeling methods with
small molecules will be discussed, followed by a brief review on protein evolutions for site-
specific labeling in Part 2. Lastly, two small molecule ligases, which are main focuses of this
thesis, will be discussed in depth.
Part 1. Current methodologies for site-specific labeling of proteins in live cells
Multiple methods have emerged for site-specific protein labeling with small
molecules in recent years' 8. Common strategies of these methods are to employ a protein or
peptide handle, which is genetically fused to the protein of interest. Small molecule probes can
be subsequently recruited to this handle through either a covalent linkage or a high affinity
non-covalent binding interaction. In this section, currently reported labeling methods are
evaluated with particular focus on their application to live cell imaging. Table 1 at the end of
this section summarizes the relative advantages and drawbacks of the methods.
Small molecule labeling using protein handles
A number of proteins can specifically bind certain small molecules, which are often
enzyme substrates or ligands for specific receptors. These highly specific interactions have
been well exploited to guide various chemical probes to proteins of interest. Protein handles
using binding interactions include Escherichia coli dehydrofolate reductase (DHFR), FK506-
binding protein (FKBP12, as a F16V mutant), and single chain antibodies. Israel and
coworkers used fluorescent derivatives of methotrexate, an inhibitor of DHFR, to visualize
cellular proteins fused to mammalian DHFR in DHFR-deficient Chinese hamster ovary
(CHO) cells9. Similarly, FK506 analog SLF' (synthetic ligand for FKBP12 F36V mutant) was
constructed to bind to this mutant form of FKBP12 (F36V) with a good affinity (94 pM) but
not to the endogenous FKBP12 in NIH-3T3, COS-7, Jurkat, and HeLa mammalian cell lines.
SLF' has a fluorescein moiety, which enables specific fluorophore labeling of FKBP12 (F36V)
fusions in cells. Farinas and Verkman also demonstrated that single-chain antibodies fused to
localization signal sequences can be used to target various hapten-fluorophore conjugates to
specific subcellular compartments of the secretory pathway in live cells". Due to their non-
covalent properties, however, they are unsuitable to long-term labeling. Dissociation of ligands
from the protein handles inevitably decreases the signals over time.
Covalent linkage between proteins and small molecules is superior in that perspective,
and protein handles such as E. coli dehalogenase (commercialized as Halotag, Promega),
human DNA repair protein 0 6-alkylguanine-DNA alkyltransferase (hAGT), and cutinase have
been successfully utilized to covalently attach chemical probes via their corresponding
substrate derivatives. For example, a modified 33-kDa bacterial dehalogenase domain has
recently been developed by Promega 2 . Wild type dehalogenases break down haloalkanes in a
two-step reaction, involving alkyl transfer to an active site Asp side chain (and the loss of the
halide ion) followed by hydrolysis of the alkyl-enzyme bond (releasing alkyl probes)13. An
active site His residue is necessary for the hydrolysis, mutation of which preserves the alkyl-
enzyme conjugates. Since eukaryotes lack dehalogenases, His mutated dehalogenase fusion
proteins can be labeled with haloalkane derivatives with a very low background staining in
cells. Johnsson and coworkers also demonstrated that cell permeable 0 6-benzylguanine
derivatives containing a fluorophores, biotin, haptens, or other protein ligands can be linked to
Cys 145 of hAGT14 . The labeling was performed with nuclear, cytosolic, cytoskeletal, and cell
surface proteins in E. coli, yeast, and hAGT-deficient mammalian cells. The fungal enzyme
cutinase and its suicide inhibitor p-nitrophenyl phosphate are used to attach a variety of labels
to the integrin lymphocyte-associated antigen-I (LFA- 1) on the surface of live cells' ". The size
of most protein handles, however, is rather large (80 - 297 amino acids), which is a major
drawback of these methods.
Small molecule labeling with peptide handles using binding interaction
Reducing the size of targeting tags using smaller peptides, however, brings a new
challenge; the strength and specificity of peptide interactions with small molecule probes are
mostly lower than those of proteins. As long as these peptides can be recognized by their
interaction partners at a high signal to noise ratio, however, peptides are clearly more
favorable since they can be fused not only to termini but also to loops of protein of interest,
without perturbing the structure and function of the protein. His6-tag16 , which has been widely
used for protein purification, was applied to label proteins in living cells, and the tetracysteine
FlAsH binding sequence17 was also used for imaging connexins in gap junctions. Furthermore,
ReAsH, a red fluorophore derivative of FlAsH, can generate reactive oxygen species for light-
assisted protein inactivation in functional studies or diaminobenzidine precipitation in electron
microscopy18 . These peptide handles, however, also show several limitations in protein
labeling. The His6-tag method suffers from inadequate specificity and a non-covalent linkage
which has a rather fast off rate. The FlAsH method also has fairly low sequence specificity
(monothiols are labeled by FlAsH as well)'19,20, a slow labeling kinetics2 1, an inability to work
in oxidizing cellular compartment such as secretory pathways 22 , and no demonstrated
successes on structures other than xanthene-based fluorophores. New complex of
polyhistidine-zinc-zine chelating dye (called HisZiFit) has been developed by Tsien and
coworkers23 . Their binding is fairly tight (Kd = 40 nM), but the dye shows suboptimal
characteristics such as low photostability and high background staining. Another zinc chelator
DpaTyr has been shown to bind polyaspartate residues with low Kd (1.4 pM)24 . These zinc
chelating dyes, however, are not membrane permeable, and the concentration of zinc
necessary for labeling is much higher than physiological concentration of zinc. A lanthanide
binding aptamer is also available for luminescence imaging, and a Texas Red binding
aptamer was reported but yet needs to be shown in cellular context26
Small molecule labeling with peptide handles using enzyme-catalyzed covalent ligation
Enzymatic coupling of chemical probes to peptide handles offers a potentially high
signal to noise ratio due to the selectivity of the enzyme. Our laboratory developed new
methodologies of cellular protein labeling which address many of the deficiencies of FlAsH
and other labeling methods2 7. A 15-amino acid acceptor peptide ("AP",
GLNDIFEAQKIEWH) is fused to the protein of interest, and then a ketone analog of biotin is
specifically ligated to a lysine side chain (underlined) within this sequence using the E. coli
enzyme biotin ligase (BirA). The reaction depends on ATP, which is used to activate the biotin
as an AMP ester. The labeling reaction is extremely sequence-specific because BirA is highly
specific for the AP peptide and does not biotinylate any endogenous mammalian proteins. As
ketones are absent from cell surfaces, the enzymatically introduced ketone can be selectively
derivatized with diverse hydrazide- or hydroxylamine-functionalized probes. BirA/ketone
labeling is currently limited to cell surface applications because of the imcompatibility of
ketone-hydrazide (or hydroxylamine) ligation with intracellular applications. Sarah Slavoff in
the lab reported that biotin ligase from Pyrococus horikoshii can incorporate an azide or
alkyne analog of biotin (DTB-Az or PB, respectively) onto p67, which is one of the
endogenous biotinyl domains of human biotin ligase28 . Unfortunately, the reaction rates of
these analogs are too low to be used for live cell labeling at this point. Also, P horikoshii
biotin ligase did not use AP as a substrate, which is another barrier for the biotin ligase system.
In light of this result, Marta Femandez-Suarez in the lab developed a new labeling
methodology using E. coli lipoic acid ligase (LplA), which is structurally related to biotin
29ligase and can attach a lipoic acid prosthetic group to pyruvate dehydrogenase . Instead of
lipoic acid, 7-azidoheptanoic acid was incorporated to a lipoic acid acceptor peptide tag (22
amino acids) by LplA, and then the azide was derivatized with a cyclooctyne-conjugated
fluorophore. Although the methodology was only demonstrated on cell surface proteins, the
absence of azide and cyclooctyne inside cell will potentially help the methodology being
extended to intracellular labeling. Moreover, we have found that LplA is more tolerable to
point mutations in active site and thereby accepts many different substrate probes such as aryl
azide analog 30 , coumarin analog, and so on. A detailed procedure for the development of the
methodology with an aryl azide analog is discussed in Chapter 5 with its advantages,
limitations, and suggestions for future development.
Another method that enables single-step labeling is Bacillus subtilis
phosphopantetheine transferase (PPtase; called Sfp)-catalyzed ligation of diverse CoA
derivatives to the ybbR peptide tag 1 . Originally, the labeling was performed with a protein
recognition sequence (-80 amino acids) derived from either peptide carrier protein (PCP) 32 ,33
or acyl carrier protein (ACP)3 4 . More recently, Yin and Walsh have identified a 12-amino acid
sequence that serves as a specific substrate for Sfp (called "ybbR"). PPtase possesses wide
small molecule substrate tolerance, and it also shows high specificity for its peptide substrate
comparable to those of BirA and LplA. PPtase-based labeling is currently limited to
extracellular tagging because CoA is cell impermeant and intracellular use would require
proper conjugation of functional groups to CoA by endogenous biosynthetic pathways.
Other enzymes used for extracellular tagging include the bacterial enzyme sortases,
which cleave the Thr-Gly amide bond in LPXTG sequences and ligate the resulting COOH
terminus to pentaglycine peptide derivatives3 5 . The large polar surface areas of these peptide
analogs, however, prevent cellular entry. The use of transglutaminase (which has been
harnessed by our laboratory) is limited by low specificity to its peptide substrate, although the
enzyme can handle diverse amine substrates36. Farnesyltransferases can mediate attachment of
a variety of farnesyl derivatives to the cysteine residue in the COOH-terminal sequence CVIA,
but the presence of endogenous targets again precludes their uses inside cells.
Genetic incorporation of unnatural amino acids
A different set of techniques allow specific protein labeling with synthetic functional
groups with single amino acid precision. Genetic incorporation of unnatural amino acids was
demonstrated in living cells38, whereas other methods such as chemical modification39 or
native chemical ligation40' 41 can be used only in vitro or with microinjections to cells.
Unnatural amino acid mutagenesis via amber codon suppression has been used to
label proteins with biophysical probes such as benzophenone4 2 and aryl azide crosslinkers 43, as
well as fluorophores such as dansylalanine44 and 7-hydroxycoumarin 5. In addition to
introducing such modifications directly, amino acids with ketone 46, azide43 acetylene47, and
thioester groups can be incorporated48 , providing new labeling reaction moieties that are
orthogonal to those of endogenous amino acids. The perfect specificity with minimum
possible structural perturbation to the protein of interest is a big advantage of the methodology.
However, the method cannot be used to incorporate unnatural amino acids that are toxic or
incompatible with the protein biosynthesis machinery (e.g., D-amino acids)2 1. Also, a new
orthogonal tRNA synthetase/tRNA pair needs to be evolved for every new probe. Another
serious concern is that a large amount of truncated protein product is inevitably generated as a
result of the competition between unnatural amber suppressor tRNA and the release factors
that normally terminate protein synthesis at the amber stop codon. This can lead to a dominant
negative effect, especially if the protein of interest is multimeric in its functional state.
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Table la. Different methods for labeling recombinant proteins with small molecule
probes in live cells and their relative attributes. The tag size is given as the number of
amino acids.
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Table 1b. Different methods for labeling recombinant proteins with small molecule
probes in live cells and their relative attributes. The tag size is given as the number of
amino acids.
Part 2. Directed evolution of proteins for site-specific protein labeling
As discussed in Part 1, many site-specific protein labeling methods employ enzymes
to get covalent linkage between a small molecule probe and the protein of interest and to
benefit from the innate specificity of the enzyme reaction, which reduces background labeling.
However, many enzymes are very specific to their original small molecule substrates and do
not use biochemically interesting probes (e.g. fluorophores) as substrates. One solution to this
problem is to use substrate analogs, which possess intended functional moieties, as
demonstrated in ketone biotin labeling by BirA. However, in most cases the analogs are not
accepted by the original enzyme due to their structural difference from the native substrate.
Site-directed mutagenesis of an enzyme in the vicinity of the substrate binding site has been
used to overcome the changes in the substrate structure, and significant success of this
'rational design' has been demonstratedsi, 52. Proper structural information for rational design,
however, is not available for all proteins. Moreover, successful design of an enzyme mutant
with new substrate specificity is often highly challenging. Directed enzyme evolution has
become a more general strategy as the method does not necessarily require structural
information on the enzyme and can cover a wide range of mutations, providing a better chance
to find properly mutated enzymes for the substrate analogs.
Biochemists have been actively trying to change the properties of biological
molecules to give them novel functions in a directed fashion (often called molecular
evolutions)53' . In evolution experiments in the laboratory, the gene encoding a protein of
interest is first (partially) randomized as described in Figure 1. From these mutated genes,
many mutant proteins are produced, forming a so called protein library. Appropriate screening
or selection methods may then be applied to select members of the resulting libraries of
protein-encoding sequences
are randomized
IF
Proteins are expressed from
the library
Each member is assayed
individually
All are under the same
conditions and only the
desirable appear
'- Eo~es the clone have the No
property we want',
jYes
New proteins 
Figure 1 Overview of directed evolution of proteins
protein mutants that have particular properties, such as the ability to bind a small molecule (e.g.
fluorophore) or to catalyze a chemical transformation (e.g. ligation of a fluorophore). The
genes for selected mutant proteins are collected and amplified for further mutations and
selections. Through iterative cycles of mutagenesis and amplification of selected mutant
protein members, beneficial mutations accumulate. In this way, populations of
macromolecules may be carefully evolved toward having new functions. Although successful
progress has been made toward these goals5 5 , evolution of biomolecules in the laboratory
remains a challenging task because functional sequences are rare compared with the almost
unimaginably large number of theoretical sequences to be sampled. In Chapter 2, engineering
of a peptide substrate will be deliberated, and in Chapter 3, Chapter 4, and Chapter 5 we will
discuss directed evolution of several proteins.
Since proteins cannot be amplified themselves, genotype (the genes encoding
proteins) and phenotype (the expressed proteins) must be linked physically to get the sequence
information. In vitro protein evolution can be categorized by strategies to generate the
genotype-phenotype linkage (Figure 2): cell-surface display5 6, phage display", mRNA
display58 , ribosome display59, and in vitro compartmentalization (IVC) 60. Here we will
compare these selection techniques with particular focuses on their advantages and
disadvantages. Chapter 2 will cover the yeast display methodology to evolve better peptide
substrate for yeast biotin ligase, and detailed discussion of IVC for evolution of BirA and
Streptavidin will be in Chapter 3 and 4.
Cell-surface display (bacterial display and yeast display)
In cell-surface display, proteins of interest are fused to a membrane protein so that they
are presented on the cell surface. Various cells, including bacteria61 and yeast6 2, can be used for
this purpose, where genotype and phenotype are contained in each cell. The advantage of cell-
surface display is that high throughputs (~105 clones/second) can be obtained with techniques
like fluorescence activated cell sorting (FACS) 63. However, compared with other methods (e.g.
in vitro compartmentalization), the size of library is limited in cell-surface display due to the
gene transformation step, which generates ~1010 clones for E. coli and ~107 clones for yeast.
Displaying antibody libraries on the surface of E. coli and binding with fluorescence-labeled
antigens resulted in antibodies with high affinities64' 65. The selection of novel enzymes was
also reported using a positively charged synthetic FRET substrate66.
A. Cell-surface display B. Phage display
Protein ProteinGene iI protein
Gene lIl Gene VIII proteinP lasmid DNA
Living cells (bacteria or yeast)
C. In vitro compartmentalization
Tagged protein
Anti-tag antibody
Gene
Water in oil emulsion
Figure 2 Strategies for genotype and phenotype linkage by (A) cell-surface display,
(B) phage display, and (C) in vitro compartmentalization. The figure was modified
from Matsuura, T.; Yomo, T.; Journal of bioscience and bioengineering, 2006, 101,
449-456.
In yeast display, a protein of interest is presented as a fusion to the Aga2p mating
agglutinin protein on the surface of yeast 67. Recent advances in applications of yeast display
include affinity maturation, protein engineering for improved production and stability, as well
as novel applications in cell-based selections, epitope mapping, cDNA library screening, cell
adhesion molecule engineering, and selections against non-biological targets68 . Particular
advantages of yeast display over other in vitro evolution methods include eukaryotic
expression and processing, quality control mechanisms (ensuring that only properly folded
proteins reach the cell surface), minimal avidity effects, and also quantitative screening
through FACS69. One drawback of yeast display is differential glycosylation in yeast
compared to mammalian cells. Systemic and high throughput examples of enzyme evolution
has not yet to be described70 , but recently horseradish peroxidase has been evolved using yeast
display to show slightly higher enantioselectivity7 1 .
Phage display
One of the most common protein evolution methods is phage display, which has been
widely used to engineer antibodies 72 and protein binders 73 . The protein of interest is displayed
on the surface of the phage and the encoding gene is encapsulated inside the phage. One
advantage of phage display is the relative robustness of the phage particle under variety of
selection conditions, which is different from yeast display. However, poor display of some
proteins on the phage surface and poor production of phage clones displaying certain proteins
have been main disadvantages of the method74.
Numerous enzymes have been displayed on the phage surface in active
conformations75 . Directed enzyme evolution by phage display requires a technique that
couples the catalytic ability of an enzyme with the binding ability acquired as a result of the
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reaction . Several examples using enzyme inhibitors or designed substrates have been
reported. Recently, novel catalytic antibodies that hydrolyze an aryl phosphate were identified
by a selection with 2-difluoromethylphenyl phosphate as substrate77 . By design, the hydrolysis
product subsequently rearranged to an electrophilic quinonemethide, which immediately
formed a covalent bond with the enzyme and its associated phage particle.
In vitro compartmentalization (IVC)
In IVC, the genotype-phenotype linkage is provided by synthetic compartments of
aqueous solutions within a water-in-oil emulsion 8 . Each compartment contains a single gene
on average. By virtue of allowing single genes per compartment, the desired activity secures
the survival of the fittest genes directly79 . Reactions in these compartments can be controlled
without compromising the chemical integrity of the droplets. Currently, IVC is the only in
vitro evolution method for enzymes because it allows multiple-turnover selection. Recent
examples of IVC include in vitro evolution of streptavidin binding desthiobiotin"0 and of Ebg
enzyme (originally with negligible 13-galactosidase activity) with high f3-galactosidase
60
activity, 
.
The expression of the protein of interest is a prerequisite for the evolution methods
described above. Differential protein expression may cause biases in selection. In order to
circumvent this problem, in vitro translation system is used in IVC, and thus protein libraries
with a higher diversity (1014) can be constructed (Other methods such as mRNA display and
ribosome display also use in vitro translation system.) However, since the selected enzymatic
reaction takes place in the same compartment where in vitro transcription and translation are
carried out, complications may arise as a result of the specific environment (pH, temperature,
ionic strength, etc.)79 Also, substrates are immobilized in most cases, and thus it will drive the
evolved enzymes to a low KM7 9.
Part 3. biotin ligase and lipoic acid ligase in E. coli
Ideal enzyme candidates for site-specific protein labeling would preferably catalyze
small molecule incorporation onto a small peptide substrate, where the reaction shows high
specificity for the target peptide and the enzyme can tolerate some degree of structural
changes of the small molecule substrate. Two E. coli protein ligases (BirA and LplA) have
been extensively studied in our lab. BirA shows high sequence specificity toward its peptide
substrate and LplA has high tolerance against various small molecule substrates.
Biotin and lipoic acid are the covalently bound cofactors of several enzyme
complexes involved in key metabolic reactions (Figure 3A and 3B)8 1. Their attachment to a
protein called biotinyl- or lipoyl domain is catalyzed by biotinyl protein ligase (BPL) or lipoyl
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protein ligase (LPL), respectively8 . BPL and LPL have a homologous catalytic module, thus
their reaction mechanism is very similar 82 ; biotin and lipoic acid are first activated to an
adenylated intermediate by BPL or LPL, and then transferred to a specific lysine residue on
biotinyl- or lipoyl domain. The reaction mechanism is analogous to that of acyl-tRNA
synthetases, suggesting a common ancestral relationship 1.
In E. coli, ligation reactions by biotin ligase (BirA) and lipoic acid ligase (LplA) are
both extremely sequence specific. Biotin carboxyl carrier protein (BCCP) is the only protein
biotinylated by BirA out of >4000 proteins in E. coli83, and LplA has only four substrates
(pyruvate dehydrogenase, 2-oxoglutarate dehydrogenase, branched-chain 2-oxoacid
dehydrogenase, and the glycine cleavage system) 84. One difference between biotinylation and
lipoylation in E. coli is existence of the second lipoylation enzyme LipB, which uses lipoyl-
acyl carrier protein (lipoyl-ACP) as the donor of the lipoyl group8 5.
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Figure 3 Reactions catalyzed by (A) biotin protein ligase, and (B) lipoic acid protein ligase.
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E. coli biotin protein ligase (BirA)
Biotin is a cofactor for many biotin-dependent carboxylases, where biotin is required
for the transfer of carbon dioxide from bicarbonate to organic acid metabolites 6 . Biotin is
covalently attached to this family of enzymes by BPL. As the biotin-dependent enzymes are
turned over, biotin is hydrolyzed off the degraded peptide fragments by biotinidase, allowing
recycling of the cofactor8 6. The biotin-dependent enzymes are all functional carboxylases and
are essential due to their involvement in fatty acid synthesis, gluconeogenesis and amino acid
catabolism8 7. BirA is a BPL of E. coli (35.5 kDa), and it also regulates the E. coli biotin
synthesis by binding to the biotin operator transcription site in the form of a BirA-biotinyl-5'-
adenylate complex, thereby repressing transcriptions of genes related to biotin synthesis 8 .
Crystal structure of biotin bound BirA shows that BirA monomer is organized in three
domains". The N-terminal domain, which contains a helix-turn-helix motif, is responsible for
binding DNA when BirA forms dimers. The C-terminal domain functions in the transfer of
biotin onto BCCP. The final domain II has biotin- and ATP-binding sites and contains several
poorly defined loop regions, which are associated with conformational changes in BirA upon
ligand binding. The biotin-binding loop (residues 116-124) becomes well-ordered after biotin
binds BirA. In addition to packing interactions with the thiophene ring and the aliphatic tail of
biotin, several hydrogen bonds are formed between the main chain atoms of Arg 116 and the
ureido ring of biotin. The carbonyl oxygen of the biotin forms hydrogen bonds with the side
chains of Arg 116 and Ser 89, and ureido nitrogens interact with the carbonyl oxygen of Arg
116 and the side chain oxygen atoms of Thr 90 and Gln 112. These hydrogen bonds are
responsible for specific binding of BirA to biotin. The adenylate binding site is fully formed
only after the biotin-binding loop is ordered88 . Arg 118 and Arg 121 make the critical
88phosphate binding interactions
The kinetic analysis of biotin ligation reaction by BirA under steady state conditions
demonstrate that the Km values for apo BCCP87 (87-residue C-terminal fragment of BCCP,
functionally identical to BCCP in biotin transfer), biotin, and ATP are 4.39 ± 0.37 PM, 0.49
0.07 pjM, and about 0.3 mM, respectively 90 . The kcat value is 0.16 ± 0.09 s-1 90.
BirA can biotinylate BPL protein substrates derived from other organisms91. BPL-
catalyzed reaction system for biotin addition is highly conserved, particularly in the region of
target lysine residues of biotinyl domains. A Met-Lys-Met motif, where the middle lysine is
biotinylated, is essentially invariant in all biotinyl domains 92. Screening for a novel peptide
substrate, which can be biotinylated by BirA, has led to the identification of acceptor peptide
(AP; peptide sequence: GLNDIFEAQKIEWHE) 93' 94. The sequence of AP bears little
similarity to the known biotinylated sequences of BCCP subunits, but the specificity constant
(kcat/KM) is nearly identical to that measured for the natural protein substrate BCCP (11,900 ±
400 M- s1 for BCCP where 10,000 ± 500 M-1 s-1 for AP) 94 . The Km value of AP is around 25
pM 94, which is higher than BCCP, and due to its small size AP will bind BirA in a different
manner where BCCP binds BirA (It would be hard to mimic the structural conformation of the
protein substrate with a 15-mer peptide.)
E. coli lipoic acid protein ligase (LplA)
Lipoic acid is an extremely widely distributed cofactor which is essential for activity
of a variety of enzymes catalyzing oxidative decarboxylations 95. The pyruvate dehydrogenase
complex of E. coli consists of three enzymes; pyruvate dehydrogenase (El), dihydrolipoamide
acetyl transferase (E2), and lipoamide dehydrogenase (E3) 96. The reaction intermediate is
transferred between these three types of active sites via linkage to the lipoyl-lysine 'swinging
arms' that are located in the E2p chains 97. The specific attachment of lipoic acid to a single
lysine of E2 domains is catalyzed by LplA (38 kDa).
Crystal structures of native and lipoic acid-bound forms of E. coli LplA are initially
reported", but structural information, providing more insights for lipoylation by LplA, was
obtained from lipoyl-AMP complex of LplA of Thermoplasma acidophilum (Ta)99. The lipoyl
group of lipoyl-AMP is buried completely inside the bifurcated pocket. The dithiolane ring
and the aliphatic chain of lipoyl-AMP are surrounded by hydrophobic residues of Ta LplA.
The side chains of two histidine residues (His 81 and His 161) and the aliphatic side chains of
Leu 18, Ile 46, Arg 72, and Ala 163 form hydrophobic environment for the dithiolane ring.
Since no hydrogen bond exists between LpIA and the lipoyl group, the substrate specificity of
LplA is apparently lower than that of BirA, which forms multiple hydrogen bonds with biotin.
In addition to its preferred substrate D-lipoic acid, LplA can also incorporates L-lipoic acid
and octanoic acid 00' 10 1.
The KM(app) value for lipoic acid incorporation by LplA under steady state conditions
is 1.7 pM100 or 4.5 IM98. The kcat value is 0.253 ± 0.003 S-129
The structural analysis shows that the lipoyl and biotinyl domains are closely related8 1.
BirA and LplA distinguish their protein substrates by the existence of the protruding thumb
region in biotinyl domains. When this thumb is removed, the biotinyl domain is almost as
efficient a substrate as the native E2p lipoyl domain for lipoylation. In contrast to the rather
free lipoyl-lysine residue in E2p, the biotinyl-lysine residue is tightly bound in E. coli BCCP
by the interactions between the biotin moiety and residues in the thumb region. Although a
large excess of LplA can lipoylate the biotinyl domain with a Met-Lys-Met motif, an Asp-Lys-
Ala motif of the lipoyl domain is not accepted by BirA for biotinylation. The peptide substrate
of LplA (Lipoic acid Acceptor Peptide, LAP) has been designed and validated by others in the
lab. BirA Acceptor Peptide AP was not lipoylated by LplA, and LAP in turn was not
biotinylated by BirA 0 2
Applications of BirA and LplA
Biotinylation has been widely used for affinity-based protein coupling in many
biological assays, since biotin binds Avidin (or streptavidin) with exceptionally strong affinity
(Kd= 10" M)io3 . Either endogenous BPL or exogenous BPL (BirA in most cases) has been
utilized to biotinylate the protein of interest which is fused to the biotinyl domain. Due to the
small size of AP (compare to native BCCP substrate protein) and the great specificity of this
peptide for the BirA reaction, biotinylation of AP fused proteins with BirA has been widely
investigated in bacteria 0 4 and mammalian cells105. BirA also specifically incorporates
desthiobiotin, a sulfur missing form of biotin, onto biotinyl domain, where the Km value for
desthiobiotin is about 40-fold higher than that for biotin'06 . More surprisingly, others in our lab
found that BirA can incorporate a ketone isostere of biotin to the target biotinyl sequence with
an only 3.7-fold lower initial reaction rate than biotin 7 . Ketones are absent from native cell
surface. Proteins on cell surfaces can be site-specifically labeled with the ketone biotin by this
BirA system and subsequently labeled with fluorophore by using the highly specific chemical
reaction between with fluorophore hydrazide and the ketone biotin. Our lab has also developed
a quantum dot (QD) targeting method using BirA/AP system and streptavidin QDs 0".
Unlike biotinylation, lipoylation has not been utilized for bioassays since no strong
binder for lipoic acid is available. As mentioned in Part 1 of this chapter, however, our lab has
demonstrated site-specific protein modification with azide by LplA29.
The major goal of my thesis work was to develop new site-specific small molecule
labeling methodologies by engineering key elements of the biotin and lipoic acid ligase
platforms. In Chapter 2, I discuss yeast display selection for kinetically improved peptide
substrates of yeast biotin ligase. The selection produced new peptide substrates for yeast biotin
ligase, but they likely have activity comparable to the previous yeast acceptor peptide
discovered by phage display 0 8. Establishment of the yeast display platform for kinetically
improved peptide substrates, however, has led to the improvement of LplA's acceptor peptide,
achieved by others in our labio2. We also attempted to engineer BirA to have faster kinetics for
AP biotinylation by using in vitro compartmentalization (IVC) as discussed in Chapter 3. A
novel bead-less IVC scheme for BirA evolution was successfully developed. Faster BirA
selection was, however, restricted by technical difficulties of IVC and the nature of the
selection (single turn-over selection). We further expanded the IVC selection strategy and
developed a platform for streptavidin evolution using IVC. The development of a new
streptavidin and biotin analog pair will extend the range of current streptavidin-biotin
technology. Selection for streptavidin variants which show high affinities toward ketone biotin
was performed with two rationally designed libraries (Chapter 4). Streptavidin evolution for
ketone biotin binding was, however, inconclusive due to the lack of suitable assays to evaluate
the progress of the selection.
We also have engineered the small molecule substrate specificity of LplA. At the start
of our work, lipoic acid, selenolipoic acid, and octanoic acid were the only known small
molecule substrates of E. coli LplA 01' 109. Among many biophysical probes, this thesis focuses
on the development of photoaffinity labels that can be incorporated onto proteins in a site-
specific manner. Compared to fluorophore labeling of proteins, targeting methods for
photoaffinity labels are highly limited. Photoaffinity labeling, however, offers additional
information that fluorophores cannot provide, such as the identity of endogenous interaction
partners for a protein of interest (even transient interactions) 10 . In Chapter 5, engineering of
LplA to incorporate a photoaffinity probe (aryl azide analog) is demonstrated.
Future directions
Many methods of site-specific cellular protein labeling have been developed during
the last decade, and we now have a better tool box to study cell biology than ever before.
Some challenges for the future include the following. First, it would be desirable to have
labeling methods that tag endogenous, rather than recombinant proteins. Recombinant proteins
are often overexpressed, and this together with their tags, can alter biological function. Some
methods exist to tag endogenous proteins, such as fluorescent ligands and antibodies, but these
are usually labile on the timescale of minutes. Second, major improvements in enzyme-based
technologies such as those developed by our lab will require successful application of in vitro
evolution and/or computational techniques. In vitro evolution has so far been most successful
for discovering novel binders, such as new antibodies. Evolving new catalytic activity is far
more challenging, but some notable examples exist, particularly with the aid of computational
methods"1 . We note that methods to evolve novel enzymes will have wide-ranging impact, not
just in cellular imaging, but also in the field of organic chemistry, such as by enabling simpler
and more environment-friendly synthesis'1 2
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Chapter 2: Improvement of Yeast Biotin Ligase Acceptor Peptide by Yeast
Display Evolution
This chapter describes the characterization and utilization of yeast biotin ligase
acceptor peptide (yAP), and subsequent efforts to evolve an improved yAP by yeast display.
The first part of this chapter has been published in Chen, I., Choi, Y. A., and Ting, A. Y.,
"Phage display evolution of a peptide substrate for yeast biotin ligase and application to two-
color quantum dot labeling of cell surface proteins." J. Am. Chem. Soc. 129, 6619-6625 (2007).
Description of my specific contribution: I joined the project after yAP was evolved
via phage display by Irwin Chen, a former graduate student in the Ting laboratory. While he
characterized yAP using phage ELISA assays, I investigated the orthogonality of yAP and AP
(the peptide substrate for E. coli biotin ligase) on yeast cell surface. I also characterized yAP
and AP orthogonality on purified AP and yAP fusions to cyan fluorescent protein (CFP) and
heterochromatin protein 1 (HP1). I helped to develop the labeling protocol for orthogonal QD
targeting to yAP and AP fusion proteins on the mammalian cell surface.
The project involving yeast display evolution of yAP was performed independently,
without collaborators.
Introduction
Biotinylation is widely used for protein labeling, immobilization, and purification as
reviewed in Chapter 1. This is mostly due to the strong interaction between biotin and
(strept)avidin and to the existence of a peptide substrate (AP) 2,3 for biotin ligase. AP is a 15
amino acid peptide which is specifically biotinylated by BirA, the E. coli biotin ligase. It has
been desirable to develop a protein labeling strategy with similar specificity using small tags.
Moreover, if the reactivity of the new method is independent from that of the BirA reaction,
both methods can be simultaneously utilized for multiple protein labeling. For example, many
biological processes such as signal transduction involve several proteins, and by labeling (and
thus monitoring) multiple proteins at the same time, we can get more insightful information on
the biological event.
In order to achieve this goal, Irwin Chen in our lab tested biotinylation of AP using
biotin ligases from other organisms, and observed that biotin ligases from Bacillus subtilis,
Methanococcus jannaschii, yeast (Saccharomyces cerevisiae)4 and humans5 do not use AP6
He then used phage display to select peptide substrates that are active for biotin ligases from B.
subtilis, M. jannaschii, and S. cerevisiae (bsBL, mjBL, and yBL, respectively). There was an
increase in biotinylation activity over three rounds, and only yBL was found to be responsible
for the peptide biotinylation. The selected peptides contained a common Met-(Thr/Glu)-Phe
motif immediately following the biotinylation site lysine. Thus, the second generation
selection was performed with a new library including the Met-(Thr/Glu)-Phe motif (34% of
the library contained the sequence of this motif). The best peptide derived from the selection
was named as yeast acceptor peptide (yAP). Characterization of yAP and its application to
mammalian and yeast cell surface labeling will be discussed in Part I of the present chapter.
Although we were able to demonstrate orthogonal labeling of AP- and yAP-fusion
proteins on cell surface, the catalytic efficiency for the biotinylation of the yAP by yBL was
still 780 times worse than that reported for the biotinylation of the AP by BirA3 . It was mostly
due to a poor kcat of yAP, which indicated the need of multiple turnover selection condition to
improve the kinetic property of yAP. A model phage display selection was performed with
yAP and the 2-3-5 peptide which is biotinylated by yBL about ten fold worse than yAP. With a
1:20 mixture of yAP-phage and the 2-3-5 phage, Irwin Chen could not see any enrichment of
yAP over the 2-3-5-phage, indicating that the phage display system used for the selection does
not provide the necessary dynamic range to distinguish between the two substrates for yBL.
Yeast surface display is a powerful tool for protein engineering, by which a protein can
be evolved to get improved or novel binding affinity, catalytic activity, and/or structural
properties such as high stability and better expression 7. Developed by Boder and Wittrup about
ten years ago , numerous examples of yeast display application have been reported,
particularly in therapeutic antibody engineering. Other utilization for protein characterization,
including the mapping of functional epitopes mediating protein-protein interactions 0 , is
emerging as well. Furthermore, proteins that target insoluble or unknown molecules are also
engineered using yeast display". Yeast cells can also serve as a physical support where
proteins are immobilized, replacing solid resins".
Yeast display has several advantages over the phage display. First of all, the use of
fluorescence-activated cell sorting (FACS) allows quantitative screening where one can
observe the statistics of sample directly during the process 3 . Using double labeling of yeast
cells, the antigen-binding signal can be normalized with surface protein expression,
eliminating artifacts due to expression bias14 . Recently, Bowley and coworkers compared the
two methods (the phage and yeast display) using identical antibody libraries and antigens15 .
The study showed that yeast display samples the members of a library considerably more
fully 5 . In addition, the number of protein copies displayed on the surface is 104 - 105 for yeast
whereas 3 - 5 for pIII protein or 2700 for pVIII protein of wild type M13 phagel'. We
envisioned that yeast display is more suitable to evolution of our peptide substrates than phage
display since it will allow multiple turnover selection and finer discrimination between
mutants.
In Part II of the present chapter, our attempts to improve the catalytic activity of the
current yAP peptide substrate of yBL will be discussed. By performing a model selection with
kinetically repressed peptides, we have successfully confirmed that yeast display actually
provides a multiple-turnover condition for selection of yBL peptide substrates. The developed
yeast display method for turnover-based yBL substrate selection will offer an excellent
platform for further investigation of yAP/yBL labeling methodologies. In our knowledge, this
is the first example of yeast display for peptide substrate evolution. Indeed, Dr. Sujiet
Puthenveetil showed that LAP2 (LplA acceptor peptide 2), which has a >70 times better
kcat/KM than the rationally engineered LAP", could be evolved using the yeast display system
with a covalent product capture method18 . LAP2 has almost same catalytic efficiency as a
natural protein substrate for LplA.
Results and Discussion
Part . Characterization and applications of phage-evolved yAP peptide
Summary of Irwin Chen's work Irwin Chen performed a model selection with a native AP
peptide (GLNDIFEAQKIEWHE) and an Ala mutant (GLNDIFEAQAIEWHE), where the
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Figure 1 Design of the peptide library for yeast display selection based on AP2.2
library. The sequences of the AP, biotin ligase substrate proteins from four different
species (E. coli BCCP (biotin carboxyl carrier protein), B. subtilis ACC (acetyl CoA-
carboxylase), M jannaschii ODC (oxaloacetate decarboxylase), and S. cerevisiae
PCI (pyruvate carboxylase 1)) and the first-generation AP2 library are shown for
comparison. The lysine biotinylation sites are underlined. Red positions are
completely randomized, while blue positions are partially randomized (-34% the
indicated amino acid). This figure was reproduced from reference 6.
lysine biotinylation site is mutated to alanine. The AP and Ala peptides are displayed as a
fusion to the pIII coat protein of M13 bacteriophage. The 1:100 mixture of AP-phage and Ala-
phage was biotinylated by BirA, and the biotinylated phages were purified by streptavidin
beads. Re-amplification of the collected phage gave a 2000-fold enrichment of AP over Ala.
The new peptide library was designed as follows. Five residues that are well-
conserved in the protein substrates of biotin ligases in other organisms were fixed, and other
residues except the lysine biotinylation site were fully randomized (Figure 1, AP2 library). The
first generation of selections was then performed with 100 nM of three biotin ligases (bsBL,
mjBL, and yBL), and the E. coli strain BM4092F' was used to produce phages in biotin-
depleted media for the first two rounds of selection. This strain does not biosynthesize biotin,
and it expresses a mutant of BirA with a higher Km value for biotin. Use of this strain,
therefore, removed the background biotinylation by endogenous BirA in E. coli, and a few
members of the library which are biotinylated by the mixture of three biotin ligases could be
maintained at earlier rounds of selection. Subsequent ELISA assays with each biotin ligase
showed that only yBL was responsible for the biotinylation activity in the selection.
Evaluating individual clones from the third and fourth rounds by sequencing revealed that all
peptides biotinylated by yBL contained a Met-(Thr/Glu)-Phe motif immediately following the
lysine. Therefore, the second generation of selections was performed with a new library that is
biased to the Met-(Thr/Glu)-Phe motif (Figure 1, AP2.2 library). Previously fixed residues
were mutated so that 34% of the sequences would contain the designed amino acid, while the
remaining 66% would contain any of the other 19 amino acids or stop codons (Figure 1).
Despite randomization in the design of the second generation library, the Met-
(Thr/Glu)-Phe motif re-emerged largely intact even after the second generation of selections.
The best isolated peptide was biotinylated by yBL ten-fold better than the best peptide from
the first generation selection. He named this sequence the "yeast acceptor peptide" (yAP), and
all subsequent characterizations were performed with this peptide.
Biotinylation of yAP fusion proteins I created yAP fusions to heterochromatin protein 1
(HP1) and cyan fluorescent protein (CFP), in order to test if yAP could be recognized by yBL
in various different contexts. Thus, both N- and C-terminal fusions were prepared.
Biotinylation was detected by blotting with streptavidin-horse radish peroxidase (HRP)
(Figure 2). yAP was successfully biotinylated by yBL in an ATP-dependent manner, with some
context-dependence. Biotinylation level of yAP at N-terminus of CFP was lower than that of
yAP at C-terminus of CFP. Nevertheless our results demonstrate that the yAP can be
recognized at either the N- or C-terminus of fusion proteins.
yAP-CFP CFP-yAP yAP-HP1 HP1-yAP
+ - + - ATP + - + - ATP
Streptavidin-HRP
Coomassie
Figure 2 Biotinylation of yAP fusion proteins. N-and C-terminal yAP fusions to CFP
and HP1 were biotinylated using yBL and analyzed by blotting with streptavidin-
horse radish peroxidase (HRP) conjugate. Coomassie staining confirms equal loading
of protein. This figure was reproduced from reference 6.
Orthogonality of the yAP/yBL pair We tested the orthogonality of the new yAP/yBL pair
using three assays.
First, phage ELISA assays were performed by Irwin Chen. Irwin found that yAP is not
biotinylated by BirA, and conversely that AP is not biotinylated by yBL (data not shown).
Second, working together with Irwin, we together performed orthogonal labeling of AP
and yAP fusion proteins on the surface of live HeLa cells. Each peptide was fused to a distinct
fluorescent protein marker expressed on the extracellular surface. First, we showed that yAP-
YFP-TM construct could be biotinylated with yBL, then labeled with streptavidin-conjugated
quantum dot (QD) 655. The QD targeting was specific for transfected cells (Figure 3);
neighboring untransfected cells remained unlabeled. Negative controls showed that the
biotinylation was ATP-dependent and site-specific at the lysine of the yAP sequence (Figure 3).
Next, HeLa cells that were individually transfected with yAP-YFP-TM or AP-CFP-TM
were mixed together to populate the same dish. The cells on the dish were then biotinylated by
yBL for 1 h at 30 *C, stained with streptavidin-QD655, biotinylated by BirA for 5 min, and
stained with streptavidin-QD565. Figure 4 shows that yAP-displaying cells were only labeled
YFP + DIC ODG55
-ATP
negative
control
yAla
negative
control
Figure 3 Site-specific biotinylation of yAP expressed on the surface of live HeLa
cells. HeLa expressing the yAP-YFP-TM construct were biotinylated with yBL for 1
h at 32 0C and detected by staining with streptavidin-QD655 for 5 min. Negative
controls with ATP omitted, or yAP-YFP-TM replaced by its yAla-YFP-TM point
mutant (where the lysine biotinylation site is mutated to alanine), are shown. YFP
images were merged and overlaid with the differential interference contrast (DIC)
image. This figure was reproduced from reference 6.
with QD655 and AP-displaying cells were exclusively labeled with QD565, demonstrating
that the orthogonality of yAP/yBL was also preserved on the mammalian cell surface.
Third, I performed an assay to test yAP and AP labeling on the surface of live yeast
cells. Irwin Chen prepared AP and yAP fusions to the Aga2p mating protein of yeast. Each
peptide was successfully biotinylated only by the matching biotin ligase, as confirmed by
streptavidin-phycoerythrin (PE) labeling and subsequent fluorescence-activated cell sorting
(FACS) analysis (Figure 5). Both fusion proteins were displayed at the same levels on yeast
cell surface, as indicated by anti-myc tag staining. No fluorescence signal was observed when
the central lysine residue in yAP is mutated to alanine or when ATP is not available.
A technical note is that while performing orthogonality tests, we observed that yBL
samples were often contaminated by endogenous BirA from E. coli cells, in which the yBL
was overexpressed. To remove this contaminating BirA, we incubated yBL samples with
1. AP YFP TM -+ ODG55
2. AP P TM -*D565
Figure 4 Selective labeling of live HeLa cells expressing yAP or AP fusion proteins
(domain structures shown at top) with quantum dots. First, yAP-expressing cells
(indicated by YFP fluorescence) were selectively labeled with streptavidin-QD655
conjugate, using yBL biotinylation. Then, AP-expressing cells (indicated by CFP
fluorescence) in the same dish were labeled with streptavidin-QD565 conjugate,
using BirA biotinylation. CFP and YFP images were merged and overlaid with the
DIC image. This figure was reproduced from reference 6.
anti-BirA antibody and pulled down with secondary antibody-conjugated beads.
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Figure 5 Orthogonal labeling on yeast cell surface. (A) Constructs used for peptide
display on yeast surface. The Aga2p fusions were anchored to the yeast cell surface
via disulfide bonds to the Agalp protein. (B) Yeast cells expressing the yAP or AP on
their surface were biotinylated with either yBL or BirA. After staining with
streptavidin-phycoerythrin conjugate, yeast cells were analyzed by flow cytometry.
The histograms show the number of cells (y-axis) counted at different fluorescence
intensities (FL2, x-axis). (C) The alanine mutant of yAP (yAla) was used as a
negative control. The fluorescence histogram is shown after treatment with yBL as in
(B). (D) To verify similar levels of surface expression, the yeast cells were stained
with an anti-myc antibody, followed by anti-mouse antibody conjugated to
phycoerythrin. Typically, 20 - 25% of the yeast cells did not display any Aga2p
fusion, and thus did not become labeled (*). This figure was reproduced from
reference 6.
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Part II. Yeast display evolution of improved yAP sequences
Model selection (1) Two different model selections were performed to confirm that yeast
display selection can provide multiple turnover selective pressure. First, model selections were
performed to enrich yAP over yAla (where the active lysine residue is mutated to alanine)
(Figures 6 and 7). Since the genes encoding these constructs have the same sizes, we created a
restriction enzyme site (BstXI) on the DNA sequence of yAla in order to distinguish it from
yAP by the restriction digestion pattern.
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Figure 6 Schematic illustration of yeast display evolution of yAP. (A) The yAP
library (blue) is displayed on the yeast surface as a fusion to Aga2p protein. A C-
terminal myc epitope is used to quantify yAP expression level. (B) Yeast cells
displaying three sample yAP sequences, with high (yAPx), moderate (yAPy), and
low (yAPz) activity are shown. After reaction with yBL, the yeast cells are
collectively labeled with streptavidin-phycoerythrin. The yeast pool is then sorted on
the basis of both ligation extent (red probe intensity) and yAP expression level (myc
staining intensity), to enrich the most kinetically efficient yAP peptides (such as
yAPx).
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Figure 7 Model selection (1). (A) Yeast cells expressing yAP or yAla on their surface
were biotinylated with yBL. After staining with streptavidin-phycoerythrin (PE)
conjugate, yeast cells were analyzed by FACS. To verify similar levels of surface
expression, the yeast cells were also stained with an anti-myc antibody (mouse),
followed by anti-mouse antibody conjugated to Alexa 488. (B) Determination of
sorting conditions for model selections. Yeast cells displaying yAP or yAla were
mixed in 1:100 or 1:1000 ratios (yAP: yAla), and biotinylated with 4.7 pM yBL at
room temperature for 3 h. After staining as in (A), cells were sorted using FACS. The
FACS scatter plots show the distribution of yeast cells as functions of PE staining
intensity (reflecting extent of biotinylation; y-axis) and myc staining intensity
(reflecting expression level of the Aga2p yAP fusion; x-axis). A cell population in Q3
is present in all samples, and represents untransfected yeast. Yeast cells in Q2 were
collected for the model selections. (C) Results of model selections. PCR reaction
followed by digestion with BstXI gives the ratio of yeast populations pre- and post-
selection. yAP enrichment factor was -80-fold.
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Yeast cells separately transformed with yAP and yAla plasmids were grown under
identical conditions. Prior to the induction of fusion protein expression, we mixed yAP and
yAla yeast cells in 1:10, 1:100, and 1: 1000 ratios (yAP: yAla). After 24 h of induction, the
yeast cells were biotinylated with 4.7 kiM yBL at room temperature for 3 h. The yeast cells
were then labeled with streptavidin-phycoerythrin and anti-myc antibody (mouse) followed by
anti-mouse secondary antibody conjugated to Alexa 488 fluorophore. The doubly labeled cells
were sorted using FACS based on their fluorescence intensity in both phycoerythrin and Alexa
488 channels. The collected yeast cells were grown in selective media with glucose as a
carbon source and antibiotics to prevent any contamination by bacteria. DNA was extracted
from the yeast using the standard 'zymo-prep' protocol. The genes were then PCR-amplified,
and the BstXI restriction enzyme was added to the PCR products. Finally, the reaction mixture
was analyzed by an agarose gel. As shown in Figure 7, yAP is fully enriched over yAla after
selection from the 1:10 mixture and we observed partial enrichments of yAP in the 1:100 and
1:1000 mixtures as well. The overall enrichment factor for the selection was calculated to be
~80-fold, which indicates that yeast display can be used to discriminate active substrates from
completely inactive ones.
Model selection (2) We performed a different model selection to determine if yeast display
could enrich highly active peptides over moderately active ones. We used the BirA system
instead of yBL. AP peptide was mixed together with AP Gln (-1) -+Glu mutant (AP Q--E).
With this mutation (the glutamine residue is located right before the biotinyl lysine site), the
biotinylation by BirA is slightly reduced compared to AP. When biotinylated with 0.3 pM BirA
at room temperature for 1 h, the fluorescence intensity in phycoerythrin channel (the
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Figure 8 Model selection (2). (A) Yeast cells expressing the AP or AP Q -E (Gln right
before the lysine biotinylation site in AP is mutated to Glu) on their surface were
biotinylated with BirA. After staining with streptavidin-phycoerythrin (PE) conjugate,
yeast cells were analyzed by FACS. To verify similar levels of surface expression, the
yeast cells were stained with an anti-myc antibody (chicken), followed by anti-chicken
antibody conjugated to Alexa 488. (B) Determination of sorting conditions for model
selections. Yeast cells displaying AP or AP Q-*E were mixed in 1:10, 1:100 and 1:1000
(AP: AP Q-+E) ratios and biotinylated with 0.3 pM BirA at room temperature for 1 h.
After staining as in (A), cells were sorted using FACS. The FACS scatter plots show
the distribution of yeast cells as functions of PE staining intensity (reflecting extent of
biotinylation; y-axis) and myc staining intensity (reflecting expression level of the
Aga2p AP fusion; x-axis). A cell population on the lower left is present in all three
samples, and represents untransfected yeast. Optimized sorting gates, used for the
model selections, are shown in rectangles. (C) Results of model selections. Genes from
mixtures of yeast cells pre and post-selection were PCR-amplified and digested with
BstBI. AP enrichment factor over mutant peptide was ~1000-fold.
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extent of biotinylation) for the yeast displaying AP was ~3 times higher than the yeast
displaying AP Q-*E (Figure 8A). We again created a restriction site (BstBI) on the DNA
sequence of the AP Q--E so that we could distinguish AP from the AP Q-*E on an agarose gel.
The model selection was performed with AP and AP Q--E expressing yeast cells mixed in
varying ratios. After biotinylation by BirA and analysis by PCR and restriction digestion, we
observed enrichment of AP over AP Q-*E by 1000-fold. Thus, yeast display provides enough
dynamic range to distinguish excellent substrates from substrates that show less activity, which
cannot be achieved by phage display. The present yeast display system, therefore, proved to be
a promising methodology to improve the kinetics of phage-evolved yAP. Model selection (2)
(AP vs AP Q--E) gave better enrichment than model selection (1) (yAP vs yAla). One
explanation for the higher enrichment factor in model selection (2) could be the use of chicken
anti-myc antibody (IgY). IgY antibodies generally show higher affinities against the target
proteins than IgG antibodies 9 . The model selection (1) (yAP vs yAla) was performed with the
mouse anti-myc antibody (IgG). Thus, the antibody might dissociate from the yeast cells much
faster, which leads to the loss of cells displaying yAP since sorting gates for model selections
were drawn for yeast cells that are positive for both expression and biotinylation. By
conserving the expression signal, we could position more double-positive cells in the sorting
gate in the model selection (2) (Figure 7B vs Figure 8B). Following selections with the AP2.2
library were performed using chicken anti-myc antibody as well. Another explanation could be
the higher fluorescence intensity of cells displaying AP compared to those displaying yAP. The
sorting gate for yAP yeast cells was drawn closer to untransfected or sick cells. When yeast
cells are not healthy, they are particularly prone to non-specific sticking toward labeling
reagents, which might decrease the enrichment factor of model selection (1). The fluorescence
intensity of AP yeast cells is higher than yAP yeast cells, and therefore the sorting gate is
drawn in a way that less false positive cells are included.
Library design For our selections, we used the same AP2.2 library that Irwin had designed
and constructed for his second-generation phage display selections. After incorporation into
the yeast surface expression construct, we checked the library by sequencing five clones at
random (Figure 9). All 14 residues were highly mutated and we did not observe any
dominance of a certain sequence.
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Figure 9 Sequences of the AP2.2 library for yeast display. The design of AP2.2
library is shown in the first row. The lysine biotinylation site is in red. Black
positions (X) are completely randomized, while blue positions are partially
randomized so that -34% of clones have the indicated amino acid sequence. Stop
codon is represented as a star.
Selections with AP2.2 library The peptide library was transformed into EBY100 yeast cells.
Transformation efficiency was ~ 106 cfu/pg, which is usual for yeast display experiments. In
order to see the level of surface expression, the transformed yeast cells were labeled with an
anti-myc antibody (chicken) followed by anti-chicken secondary antibody conjugated to Alexa
488 fluorophore. Analysis by FACS showed that about 40% of yeast cells were expressing the
myc tag (Figure 10).
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Figure 10 Myc expression of AP2.2 library after transformed to yeast cells. Among
all yeast cells analyzed, 40.16% (sub-population in Ml region; arrowed) of cells were
expressing the myc tag, which can be detected by anti-myc antibody (chicken) and
Alexa 488-conjugated anti-chicken antibody. The Ml region was manually drawn
based on the myc expression of untransfected yeast cells.
In the first round of selection, yeast cells were treated with 5 pM yBL at room
temperature for 3 h. 0.3% of the yeast cells showed positive signal for both phycoerythrin and
Alexa 488, and these cells were collected and amplified for the next round of selection. For the
second round of selection, cells were treated with 5 pM yBL for 1.5 h. For the third round, we
used 5 pM yBL for 1.5 h.
We tested biotinylation of recovered cells from each round by yBL and BirA.
Compared with the cells before selection, the biotinylation extent of yeast cells by yBL was
increased after each round of selection (Figure 11), but BirA biotinylation remained as low as
before (data not shown).
However, compared to the phage-evolved yAP sequence, we did not observe higher
activity in our yeast-evolved pools. This may be a consequence of the conditions used for the
yeast analysis, or it may reflect the limitations of our selection or the AP2.2 library. Further
characterization was not performed.
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Figure 11 Three rounds of yeast display selection with the AP2.2 library. Selection
conditions are given above each arrow. Following each round of selection, collected
yeast pools were amplified and uniformly biotinylated with 1.67 pM yBL at room
temperature for 3 h. Row A shows the FACS scatter plot for each round (myc
intensity on x-axis, biotinylation intensity on y-axis). Row B shows histograms of
Alexa 488 channel showing the extent of peptide expression. Row C shows
histograms of phycoerythrin channel showing the extent of biotinylation by yeast
biotin ligase. The last column shows similar characterization of Irwin Chen's phage-
evolved yAP, for comparison.
Conclusions
Here we have developed a yeast display system to engineer the peptide substrates of
yeast biotin ligase (yBL). At the outset of the project, yeast display had not previously been
used to evolve novel enzyme substrates. By performing two model selections, we
demonstrated that the current yeast display method offers a wider dynamic range than the
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previously used phage display format. We assume that this is mainly due to the availability of
more copies of displayed peptides and the dynamic range of FACS. These features of yeast
display enabled discrimination of kinetically superior substrates from inferior ones, with an
enrichment factor of ~1000.
Following three rounds of yeast display selection of the peptide library with yBL, the
enriched library had activity comparable to Irwin's phage-evolved yAP, although analysis
under a wider range of conditions could reveal differences. There was, however, clear
enrichment of activity towards yBL, indicating some degree of success in the selection
approach.
Also, designing a new library would be another venue for the development of better
yBL substrates. Since our knowledge of yBL is still insufficient and the crystal structure of
yBL or the yeast biotinyl domain (yPC-104)20 is not available, it would be harder to design a
new library by methods other than using highly conserved sequences from different biotinyl
domains. The Met-Lys-Met motif is conserved in almost every biotinyl domains in other
organisms, but neither AP nor yAP contains the motif One possibility would be to utilize the
lipoyl domain since biotinyl and lipoyl domains have structural homology as mentioned in
Chapter 1. Designing a library with shorter length (12 amino acids as LAP2 peptide) and
different positions of the biotinyl lysine would be helpful to find a better yAP as well.
Preparation of yBL should be improved as well. Purification by anti-BirA antibody
cannot completely remove the endogenous BirA coming from bacterial expression, and the
residual BirA can drive the selection to enrich substrates used by BirA. It is especially
disrupting since the design of library has significant similarity to AP. Another problem is the
proteolysis of yBL when expressed in E. coli". To remove any BirA contaminants and prevent
the proteolysis, expression of yBL in yeast has been investigated, although we have faced
several technical difficulties. Recently, a biotin ligase from Candida albicans was expressed in
the yeast vector pVT1 00u2 2 . They reported a high yield of protein expression (up to 13
mg/mL) and more importantly did not observe the proteolytic ligase product.
The yAP should also allow for the production of site-specifically biotinylated proteins
in live yeast, a tool that should be useful to those who study yeast cell biology or use yeast for
heterologous expression of proteins. However, due to technical problems, we could not prove
this yet.
Our peptide selection scheme is general and should enable the discovery of more
peptide substrates for biotin ligases of other species, conferring the benefits of site-specific
biotinylation to proteins expressed in those cells and organisms. The discovery of peptide
substrates for biotin ligases that do not recognize yAP and AP would also allow the
multiplexing of all applications of site-specific biotinylation, including multicolor imaging.
Moreover, the discovery of new orthogonal acceptor peptide/biotin ligase pairs will be
necessary to eventually realize the goal of simultaneous labeling of different proteins with
different small molecule probes. As mentioned earlier, development of biotin 2/ streptavidin 2
would further expand the AP and yAP methodology to a true orthogonal labeling of proteins.
Experimental
Cloning of yAP-CFP. An insert containing the N-terminal yAP, linker, and the CFP was
constructed through two successive PCR reactions. For the first PCR, the CFP-AP gene was
used as the template, and the primers 4.2NyAP. F2 (5'- GCT CAG GCT TTC AAG ATG ACG
TTT GAT CCG GGC GGG ATG GTG AGC AAG GGC GA; incorporates part of the yAP
sequence TTNWVAQAFKMTFDP) and NyAPCHis. Rv (5'- TAA GAA TTC TCC TTG TAC
AGC TCG TCC AT; incorporates an EcoRI site) were used for the amplification. For the
second PCR, the product of the first PCR reaction was used as the template and the primers
4.2NyAP. F1 (5'- TAA GGA TCC CAC GAC TAA TTG GGT TGC TCA GGC TTT CAA
GAT GAC GTT TG; incorporates part of the yAP sequence and a BamHI site) and NyAPCHis.
Rv were used for the amplification. The insert was digested with BamHI and EcoRI and
ligated in-frame to similarly digested pET-21b vector (Novagen), which introduces a C-
terminal His6 tag.
Cloning of CFP-yAP. An insert containing the CFP, linker, and the C-terminal yAP was
constructed through two successive PCR reactions. For the first PCR, the CFP-AP gene was
used as the template, and the primers NHisCyAP. Fw (5'- TAA GGA TCC CCA CCA CCA
CCA CCA CCA CGG GGG GAT GGT GAG CAA GGG C; incorporates a His6 tag and a
BamHI site) and 4.2CyAP. R1 (5'- CGT CAT CTT GAA AGC CTG AGC AAC CCA ATT
AGT CGT GCC GCC GGA GGA CTC; incorporates part of the yAP sequence) were used for
the amplification. For the second PCR, the product of the first PCR reaction was used as the
template and the primers NHisCyAP. Fw and 4.2CyAP. R2 (5'- TAA GAA TTC CTT TAC
GGA TCA AAC GTC ATC TTG AAA GCC TGA GCA ACC C; incorporates part of the yAP
sequence and a BamHI site) and NyAPCHis. Rv were used for the amplification. The insert
was digested with BamHI and EcoRI and ligated in-frame to similarly digested pET-21b vector.
Cloning of yAP-HP1. For the PCR reaction, the HP1 with AP fused to the C-terminus
(HP 1AP) was used for the template, and the primers HP1N4.2. F (5'- TTT TTT GCT AGC
ACG ACT AAT TGG GTT GCT CAG GCT TTC AAG ATG ACG TTT GAT CCG GAG GAG
GAG TAC GCC GTG; incorporates the yAP sequence and an NheI site) and CHindlII. R (5'-
TTT TTT AAG CTT GCC GCC ATC CTT GCG GC; incorporates a Hindi site) were used for
the amplification. The insert was digested with NheI and HindN and ligated in-frame to
similarly digested pET-2 lb vector, which introduces a C-terminal His6 tag.
Cloning of HP1-yAP. An insert containing the HP 1, linker, and the C-terminal yAP was
constructed through two successive PCR reactions. For the first PCR, the HP lAP was used for
the template, and the primers NBamHisHP1. F (5'- TTT CGC GGA TCC GCA CCA CCA
CCA CCA CCA CGA GGA GGA GTA CGC CGT G; incorporates a His6 tag and a BamHI
site) and HP1C4.2. R1 (5'- TGA AAG CCT GAG CAA CCC AAT TAG TCG TGC CGC CAT
CCT TGC GGC TCG CCT C; incorporates part of the yAP sequence) were used for the
amplification. For the second PCR, the product of the first PCR reaction was used as the
template and the primers NBamHisHP1. F and HP1C4.2. R2 (5'- TTT CCG GAA TTC
ATT ACG GAT CAA ACG TCA TCT TGA AAG CCT GAG CAA CCC A; incorporates part
of the yAP sequence and an EcoRI site) were used for the amplification. The insert was
digested with BamHI and EcoRI and ligated in-frame to similarly digested pET-21b vector.
Western blot assays for yAP biotinylation. Proteins were biotinylated in vitro as follows: 20
pM yAP-CFP, CFP-yAP, yAP-HP1, or HP1-yAP, 5 pM yBL, 4 mM ATP, and 1 mM Biotin in
Assay buffer (40 mM Tris, 50 mM KCl, 11 mM MgCl2 pH 8.0) for overnight at 30 'C. The
samples were analyzed by 12 or 16% SDS-PAGE and blotting with either Streptavidin-HRP
(1:1000 dilution, Pierce) or anti-Histidine-tagged protein antibody (1:1000 dilution,
Calbiochem) followed by HRP-conjugated anti-mouse antibody (1:1000 dilution, Bio-Rad).
The HRP signal was visualized with Supersignal West Pico and Supersignal West Femto
(Pierce).
Cloning of pCTCon2-Aga2p-AP and pCTCon2-Aga2p-yAP for yeast cell surface labeling
(by Irwin Chen). The plasmid expressing Aga2p-AP was constructed by yeast homologous
recombination. The insert was made in two steps. First, the oligonucleotides APRev.R (5'-
AAA TAA GCT TTT GTT CGG ATC CCT CGT GCC ACT CGA TCT TCT GGG CCT CGA
AGA TGT CGT TCA GGC CTC CGC TAG CCG ACC CTC C; incorporates the AP) and
Con2For.F (5'- CTA GTG GTG GAG GAG GCT CTG GTG GAG GCG GTA GCG GAG
GCG GAG GGT CGG CTA GCG GA; incorporates -40 bp of overlap with pCTCon2 5' of the
AP sequence) were annealed and the 5' overhangs were made double-stranded with Klenow
fragment. The annealed product was then amplified with primers Con2For.F and Con2Rev.R
(5'- TAT CAG ATC TCG AGC TAT TAC AAG TCC TCT TCA GAA ATA AGC TTT TGT
TCG GAT CC; incorporates -50 bp of overlap with pCTCon2 3' of the AP). The insert and
pCTcon2 vector (a kind gift from K.D. Wittrup, triply digested with NheI/SalI/BamHI) were
transformed together into S. cerevisiae EBY100 (Invitrogen) using the Frozen-EZ Yeast
Transformation IIT kit (Zymo Research). DNA was isolated from yeast colonies using the
ZymoprepTM Yeast Plasmid Minipreparation Kit (Zymo Research) and amplified in E. coli.
The insert for Aga2p-yAP was constructed by annealing the oligonucleotides NheyAP.F (5'-
GGG TCG GCT AGC GGA GGC ACG ACT AAT TGG GTT GCT CAG GCT TTC;
incorporates an NheI site and part of the yAP) and BamyAP.R (5'- TTT TTT GGA TCC CGG
ATC AAA CGT CAT CTT GAA AGC CTG AGC AAC CCA ATT; incorporates a BamHI site
and the rest of the yAP), and the 5' overhangs were made double-stranded with Klenow
fragment. The insert was digested with NheI and BamHI and ligated in-frame to similarly
digested pCTCon2 vector. The Aga2p-yAla insert was similarly constructed using BamyAla.R
(5'- TTT TTT GGA TCC CGG ATC AAA CGT CAT CGC GAA AGC CTG AGC AAC CCA
ATT).
Yeast cell surface peptide expression, labeling, and FACScanning. Yeast strain EBY100
was used for all experiments 2. Transformation was performed using Frozen-EZ Yeast
Transformation I TM kit (Zymo Research) according to the manufacturer's instructions. After
transformation, cells were grown in synthetic minimal defined media (SD-W-U; 0.67% yeast
nitrogen base, 2% glucose, 0.01% of adenine, arginine, cysteine, leucine, lysine, threonine and
0.005% of aspartic acid, histidine, isoleucine, methionine, phenylalanine, proline, serine,
tyrosine, valine) at 30 'C with shaking for 24 h and induced in SG-W-U media (same as SD-
W-U except galactose instead of glucose) at room temperature for 24 h with shaking. Induced
cells were harvested, washed with PBSB (PBS + 1% BSA), and 2 x 106 cells in 100 p.L PBSB
were taken out for labeling experiments. For BirA reaction, cells were incubated for 3 h at
room temperature with 50 pM biotin, 0.3 pM BirA, 4 mM ATP, and Assay buffer. For yBL
reaction, cells were incubated for 3 h at room temperature with 10 pM Biotin, 4.7 pM yBL, 1
mM ATP, and 1.4 mM Mg(OAc) 2.The biotinylated cells were then washed once with PBSB,
and incubated with Streptavidin-Phycoerythrin (1:100 dilution, Jackson ImmunoResearch) for
1 h at 4 'C. For detection of myc-tag as an expression marker, anti-myc antibody (1:100
dilution, Calbiochem) was added to cells separately at room temperature. After 1 h, cells were
washed once with PBSB and incubated with anti-mouse antibody-Phycoerythrin (1:100
dilution, Invitrogen) for 1 h at 4 'C. Cells were rinsed once with PBSB and suspended in 600
ptL of PBSB for flow cytometry (FACScan, BD Biosciences).
Cloning of pCTCon2-Aga2p-yAla with BstXI restriction site and pCTCon2-Aga2p-AP
Q-+E with BstBI for model selection. The plasmid expressing Aga2p-yAla was generated
from the pCTCon2-Aga2p-yAP by following the QuikChange protocol (Stratagene) with the
oligonucleotides NewyAla(BstXI).F (5'- ACG ACC AAC TGG GTG GCT CAG GCT TTC
GCG ATG ACG TTT GAT CCG; incorporates the yAla) and its reverse complement
NewyAla(BstXI).R (5'- CGG ATC AAA CGT CAT CGC GAA AGC CTG AGC CAC CCA
GTT GGT CGT). The plasmid expressing Aga2p-AP Q-*E was similarly generated from the
pCTCon2-Aga2p-AP by QuikChange using the oligonucleotides APQ2E(BstBI).F (5'- CGA
CAT CTT CGA AGC CGA GAA GAT CGA GTG GC; incorporates 32bp of AP Q-*E) and its
reverse complement APQ2E(BstBI).R (5'-GCC ACT CGA TCT TCT CGG CTT CGA AGA
TGT CG).
Model selection (1). The yeast plasmids for expression of yAP and yAla were transformed to
EBY100 cells using the Frozen-EZ Yeast Transformation II ~kit (Zymo Research) according
to the manufacturer's instructions. After transformation, cells were grown in synthetic minimal
defined media (SD-W-U; 0.67% yeast nitrogen base, 2% glucose, 0.01% of adenine, arginine,
cysteine, leucine, lysine, threonine and 0.005% of aspartic acid, histidine, isoleucine,
methionine, phenylalanine, proline, serine, tyrosine, valine) at 30 'C with shaking for 24 h.
Yeast cells expressing yAP and yAla were mixed in 1: 10, 1:100, and 1: 1000 ratios (yAP:
yAla) before induced in SG-W-U media (same as SD-W-U except galactose instead of
glucose) for 24 h at room temperature with shaking. Induced cells were harvested, washed
with PBSB (PBS + 1% BSA), and 2 x 106 cells in 100 pL PBSB were taken out for labeling
experiments. For yBL reaction, cells were incubated for 3 h at room temperature with 10 pM
Biotin, 4.7 pM yBL, 1 mM ATP, and 1.4 mM Mg(OAc) 2. The biotinylated cells were then
washed once with PBSB. For detection of myc-tag as an expression marker, anti-myc antibody
(1:100 dilution, Calbiochem) was also added to cells at room temperature. After 1 h, cells were
washed once with PBSB and incubated with anti-mouse antibody-Alexa488 (1:100 dilution,
Invitrogen) and Streptavidin-Phycoerythrin (1:100 dilution, Jackson ImmunoResearch) for 1 h
at 4 'C. Cells were rinsed once with PBSB and suspended in 600 pL of PBSB for flow
cytometry (FACScan, BD Biosciences). For the 1:10, 1:100, and 1:1000 mixtures, 0.7%, 0.1%,
and 0.2% of the population were collected in eppendorf tubes containing 1 mL of SD-W-U
media, respectively.
Collected cells were then grown in 5 mL of SD-W-U with penicillin-streptomycin (1:
100 dilutions) for 24 h at 30 'C. DNA was isolated from yeast cells using the ZymoprepTM
Yeast Plasmid Minipreparation Kit (Zymo Research) and PCR amplified using the
oligonucleotides flanking.F (5'- CTG TTA TTG CTT CAG TTT TAG CAC) and flanking.R
(5'- GTG TAA AGT TGG TAA CGG AAC G). The PCR products were then digested with
BstXI for 1 h at 37 0C, and the reactions were analyzed in an agarose gel.
Model selection (2). The yeast plasmids for expression of AP and AP Q--*E were transformed
to EBY100 cells using the Frozen-EZ Yeast Transformation IITM kit (Zymo Research)
according to the manufacturer's instructions. Yeast cells were grown and mixed in 1:10, 1:100
and 1:1000 ratios as model selection (1). After followed the same protocol as above, yeast
cells were biotinylated for 1 h at 30 'C using 0.3 pM of BirA, 4 mM ATP, 50 pM biotin, and
Assay buffer. The biotinylated cells were then washed once with PBSB. For detection of myc-
tag as an expression marker, anti-myc antibody (1:100 dilution, Invitrogen) was also added to
cells at room temperature. After 1 h, cells were washed once with PBSB and incubated with
anti-chicken antibody-Alexa488 (1:100 dilution, Invitrogen) and Streptavidin-Phycoerythrin
(1:100 dilution, Jackson ImmunoResearch) for 1 h at 4 'C. Cells were rinsed once with PBSB
and suspended in 600 pL of PBSB for flow cytometry (FACScan, BD Biosciences). For the
1:10, 1:100, and 1:1000 mixtures, 4.2%, 0.7%, and 0.1% of the population were collected in
eppendorf tubes containing I mL of SD-W-U media, respectively. Collected cells were then
grown as above. DNA was isolated from yeast cells and PCR amplified using the
oligonucleotides flanking.F (5'- CTG TTA TTG CTT CAG TTT TAG CAC) and flanking.R
(5'- GTG TAA AGT TGG TAA CGG AAC G). The PCR products were then digested with
BstBI for 1 h at 37 'C, and the reactions were analyzed in an agarose gel.
Cloning and production of a partially-randomized 15-mer AP2.2 yeast library. The DNA
encoding the yeast library was constructed by yeast homologous recombination. The insert
was made in two steps. First, the oligonucleotides AP2.2Lib.R (5'- CAT GTT TCG GCC GAM
NNM NNA AAC GTC ATC TTC ATA GCM NNA AGA ACM NNM NNM NNM NNA GAG
TGA GAA TAG AAA GGT ACC CGG G where M=A,C and N= A,G;C,T. A represents 70% A
and 10% each of the other bases, G represents 70% G and 10% each of the other bases, and so
forth) and newAnneal.F (5'- GGG TCG GCT AGC GGA CCC CGG GTA CCT TTC TAT
TCT CAC TCT) were annealed and the 5' overhangs were made double-stranded with Klenow
fragment. The annealed product was then amplified with primers fowardsmall.F (5'- CTA
GTG GTG GAG GAG GCT C) and newreverse.R (5'- TCG GCC GAA ACA TGC GGA TCC
GAA CAA AAG CTT ATT TCT GAA GAG GAC TTG TAA TAG CTC GAG ATC TGA TA).
The insert and pCTcon2 vector (triply digested with NheI/SalI/BamHI) were transformed
together into electro competent S. cerevisiae EBY100 using electroporation. Yeast cells
expressing the library were grown in SD-W-U and passaged twice before use to reduce the
number of untransformed cells.
Selections on AP2.2 library. Three rounds of selection with yeast biotin ligase (yBL) were
performed as follows. Yeast cells (2 x 1010 cells to eliminate dead cells) were biotinylated with
5 iM yBL, 1 mM Mg(OAc) 2, 70 pM biotin, 0.7 mM ATP for 3 h (round 1) or 1.5 h (rounds 2
and 3) at room temperature. After washing and labeling with streptavidin-phycoerythrin and
anti-myc antibody followed by anti-chicken conjugated to Alexa 488, yeast cells (2 x 1 07
cells) were sorted using FACS. For round 1, 0.3% of the population was collected, and 1% of
the population was collected for rounds 2 and 3. Collected cells in SD-W-U media were grown
with penicillin-streptomycin (1: 100 dilutions) for 24 h at 30 'C.
Comparison of three rounds of selection and yAP was performed with 2 x 106 cells
using 1.67 piM yBL, 1 mM Mg(OAc) 2, 70 pM biotin, 0.7 mM ATP for 3 h.
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Chapter 3: Development of a Biotin Ligase Evolution Platform Based on In
Vitro Compartmentalization
The chapter describes the development of a novel bead-less in vitro
compartmentalization (IVC) selection scheme for BirA evolution. My specific contribution is
as follows. Based on preliminary results of Bernard Kelly and Andrew Griffiths (Medical
Research Council Laboratory of Molecular Biology, UK), Irwin Chen and Dr. Hemanta
Baruah developed a model selection with BirA and folA (E. coli dihydrofolate reductase = a
negative control lacking biotinylation activity) using IVC selection with microbeads
displaying AP fusion proteins. I joined the project later, and reproduced their model selections
successfully. However, all of us noticed problems related to the use of beads such as non-
specific sticking and bead degradation over time. Although we tried to solve those problems,
the inconsistency did not improve. Thus we decided to design a new selection scheme without
using beads.
Dr. Baruah and I equally contributed to the design and development of bead-less IVC.
I developed a protocol for peptide-oligonucleotide conjugation and purification using HPLC. I
also characterized the conjugate using MALDI-TOF. The conjugate used in the work was then
generated in large scale by Dr. Baruah and Kathy Xie, an undergraduate student in the lab. I
independently and successfully performed the model selection with BirA and folA using bead-
less IVC. I further performed a model selection with wild type and G115S BirA, and found a
lack of enrichment.
Introduction
Many natural enzymes are extremely fast catalysts; they catalyze reactions in
milliseconds which otherwise will take millions of years without catalysts'. Some enzymes are
also highly specific; they only catalyze one type of reaction with the native substrates.
Enzymatic reactions are regio-, stereo- and chemoselective 2 . The reaction specificity is
achieved by three-dimensional structure of the enzyme. For example, negatively charged
enzyme surface attracts binding of the positively charged native protein substrate.
Hydrophilicity or hydrophobicity of the side chains in the substrate binding site of enzymes is
also important to distinguish native substrates from other biomolecules.
At present, predicting the activity of an enzyme solely based on the structure is a
highly difficult task. Furthermore, engineering enzymes to have activities on substrates whose
structure are very different from native ones is also challenging 3. As it will be discussed in
Chapter 5, we were able to engineer LplA to take the aryl azide probe by semi-rational design.
However, similar rational approaches to modify BirA to accept unnatural biotin analogs were
unsuccessful in our early studies. Here directed evolution was performed as an alternative
approach for BirA engineering, which harnesses the power of natural selection. Directed in
vitro evolution consists of three vital components5: a method to generate genetic diversity; a
way to link genotype and phenotype; and a selection method for desired activity.
Library construction
Creating molecular diversity of the target protein is the first step in any directed
evolution experiment. Recent advances in chemical synthesis and molecular biology make it
practical to create mutant proteins through targeted and random mutagenesis of the gene
encoding the protein6. Although there is theoretically no limit to the number of codons that can
be randomized simultaneously, current synthetic protocols only allow 1015 different members
in a gene library5, primarily due to the limited amount of DNA that can be handled. Thus, we
are sampling only a tiny fraction of sequence space. Saturated mutagenesis of specific residues
of the protein has been used to create semi-rational protein mutant libraries. A variety of
techniques were also developed to introduce point mutations at random sites of target proteins7.
The most widely used method is error-prone PCR, which produces random mutations during
PCR by reducing DNA polymerase fidelity. This kind of techniques does not require any
knowledge on structures or molecular mechanisms of target proteins. Another powerful
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strategy is gene recombination such as DNA shuffling . By reassembling random fragments of
a gene or a pool of related genes (and also mutated corresponding genes) in a self-priming
PCR reaction, independent and beneficial mutations can occur to a single gene. Variations and
improvement on these basic methods have facilitated creation processes of novel hybrid
proteins9" 0 '.
In vitro compartmentalization: linking genotype to phenotype
As reviewed in Chapter 1, IVC is one of the best directed evolution methodologies for
enzymes5 . Compared to cell-based selections, IVC expands the scope of reactions that can be
selected (because it is not limited by the survival of the cell) and allows selection on larger
library sizes (because it is not limited by cellular transformation efficiencies). Compared to
other in vitro evolution methods, the great advantage of IVC is that a selection based on
enzymatic turnover number is possible because a large number of substrates can be included in
one compartment.
In IVC, individual genes are dispersed into separate water droplets suspended in oil (0
or 1 DNA molecule per droplet) 2"3 . Within each droplet, the gene is transcribed and translated
into protein by bacterial cell extracts. The result is that genes are co-compartmentalized with
the protein products they encode, like an artificial cell. Each microdroplet is -2 pm in
diameter with a volume of -5 femtoliters, and thus 10 compartments can be generated with a
50 ptL reaction, enabling IVC to provide a large library of proteins in a single microtube. In
addition, double emulsions (water/oil/water) can be generated when single water/oil emulsions
are re-emulsified, and these droplets can be sorted using FACS (fluorescence-activated cell
sorting), providing a direct selection without breaking emulsions' 5 . Recently, microfluidic
devices such as NanoReactorsTM were developed to create thousands of droplets per
second' 7 , and this facilitates high-throughput screening or selection.
Direct selection for catalytic activity
In vitro selection for catalytic activity is generally based on affinity-purification of the
desired product. Although successful examples are reported, indirect selections using
transition state analogs or mechanism-based inhibitors are generally limited in scope and in
the catalytic efficiency of the resulting enzymes5 . In direct selection, the selection pressure is
for substrate recognition, product formation (and reaction rate acceleration), and turnover. In
IVC, the substrate is detached from the enzyme in each compartment, and therefore the
substrate should be associated with the enzyme to be transformed to the product. Once the
reaction occurs, the product is released due to its lower affinity to enzyme than that of the
substrate. Selection for turnover can be devised if a large number of substrate molecules could
be attached to each gene (via microbeads) or a lot of soluble substrates are available in the
compartment.
IVC has been successfully employed to evolve faster forms of restriction
endonucleases 8 , DNA polymerases19 ,2 0, DNA methyltransferases''', phosphotriesterase23
f3-galactosidase from Ebg (a protein of unknown function)", thiolactonase , and ribozymes
that catalyze multiple-turnover Diels-Alder cycloadditions25 . In this chapter, our attempts to
evolve BirA mutants with a novel activity using IVC will be discussed. Although biotinylation
kinetics of BirA labeling is already sufficient for tagging of many proteins of interest, faster
BirA would be more useful especially when the BirA/AP pair is used for studying transient
protein-protein interactions26. This method employs AP-fused protein I and BirA-fused protein
II, where proteins I and II might interact with each other. If the timescale of their interaction is
shorter than that of BirA catalytic cycle, it would result false-negatives (no biotinylation
signal) even though there is interaction between two proteins. The first goal of the project was
to evolve a BirA mutant that has faster biotinylation kinetics than wild type BirA. If this is
possible, this method can also be applied for evolution of BirA mutants that uses new
interesting probes, such as aryl azide (Chapter 5).
Results and Discussion
Design and construction of a BirA mutant library
Prior to implementing a selection to evolve a faster biotin ligase enzyme, we designed
and constructed a library of focused BirA mutants. Based on the crystal structure of BirA in
complex with biotin , we selected eight positions (T90, Q112, G115, W123, G186, G204,
A205, and G206; Figure 1) lining the binding pocket which is close to a bound biotin.
Randomization of these eight residues would give a library with theoretical amino acid
Figure 1 Positions of randomized residues of BirA. Biotin was labeled in green.
Residues close to biotin and chosen for randomization were represented with ball and
stick models.
T90 0112 G115 W123 G186 G204 A205 G206 Additonal
____ ___ ___ __ _ _  _ _ __ _ __ ___mutation
LI lie Val Arg Phe Trp Asn Met Ser 881G(A)
L2 Stop Leu Phe Ser Leu Asp Ser Leu 57C(T), 312T(C)
L3 Arg Gly Arg His lie Lys lie Trp 312T(C ), 81G(A)
L4 Pro lie Arg Asp Tyr Pro Leu Cys 312T(C )
L5 Stop Ser Gly Giu His Thr Trp Thr
L6 Thr Ala Arg Ile Trp Stop Gly Leu 312T(C )
L7 Ala Stop Pro Trp Arg Met Lys Arg
L8 Met Lys Stop Asn Val Ser Gly lie
L9 Val lie Asn Asn Met Lys Ser Ser 47G(A)
L10 Asn Ala Arg Gin Gly lie Tyr Ser 491C(T)
L11 Lys Thr Ala Thr Met Arg Ile Gly
L12 Thr Val Ser Arg Gly Tyr Val Arg 312T(C),927A(G)
L13 Ala Phe Tyr Gly Trp Ser Phe Gly
L14 Ile Phe Pro Met Thr Trp Phe Arg 312A(C)
L15 Ile Pro Gly Ser Cys Cys Thr Thr 530A(T)
Table 1 Sequences of selected clones from the BirA mutant library. Additional
mutations were generated probably because of the low fidelity of DNA polymerase.
diversity of 20'= ~100. We constructed the DNA library by PCR overlap extension. Synthetic
oligonucleotides overlapping with the region of interest contained NNK (N = A, T, Q or C; K
= T or G)28 codons at the positions we wanted to randomize. The use of the K in the third
position excludes two out of three stop codons. After construction of the library, we checked
the library by sequencing 15 clones at random (Table 1). All eight amino acids were highly
mutated and we did not observe any contamination by the wild type BirA gene.
BirA evolution strategy: bead-based in vitro compartmentalization (IVC)
In bead-based IVC, an oil droplet contains single microbead, which provides a solid
support linking the gene encoding the enzyme and the product of enzymatic reaction. In
particular, streptavidin-coated beads have been widely used, where the bead captures both
biotinylated gene and also biotinylated target substrate of the enzyme23 . In our laboratory,
Irwin Chen, Dr. Baruah, and I independently performed an IVC model selection using
microbeads to test the validity of the method against BirA evolution, as shown in Figure 2.
First, commercially available carboxylate-modifed beads were functionalized with thiols, and
maleimide conjugates of streptavidin and AP-fused proteins (generated via succinimidyl 4-[N-
maleimidomethyl] cyclohexane- 1 -carboxylate (SMCC) coupling) were then added to the thiol-
functionalized beads. The copy number of protein substrates on each bead is expected to be
~105 when we assume the coupling efficiency is 100%. One molecule of biotinylated BirA
mutant gene was immobilized on each bead via binding to streptavidin (excess beads were
added to biotinylated gene). After being emulsified with in vitro transcription and translation
mixture (IVTM), only active biotin ligases expressed in vitro from the bound gene, would
ligate biotin onto the AP peptide. The beads were collected after the reaction by breaking the
emulsions, and the streptavidin-PE (phycoerythrin fluorophore) conjugate was used to detect
biotinylated AP tags on beads by FACS (fluorescence-activated cell sorter). We were able to
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Figure 2 Selection scheme for bead-based IVC. In step 1, BirA mutant genes were
attached to beads displaying AP-fused proteins, and the bead-DNA conjugates were
mixed with IVTM and segregated in individual aqueous compartments within a
water-in-oil emulsion. Within the compartments the BirA mutants are expressed from
the gene (step 2). Active mutants (left) biotinylate the AP-fused proteins on beads,
whereas inactive mutants (right) do not. After breaking emulsions, the aqueous
solution was incubated with streptavidin-fluorophore, which binds to the biotin
(represented as "B" in red) on beads (step 3). The beads were washed and sorted
using FACS based on the fluorescence intensity. The genes were recovered from the
beads through PCR after sorting for input into the next round of selection (step 4).
scan and sort out beads containing genes that express active biotin ligases. A model selection
with a mixture of wild type BirA (DNA in the left compartment in Figure 2) and folA gene
(DNA in the right compartment in Figure 2) encoding dihydrofolate reductase afforded 1000-
fold enrichment of BirA gene over folA gene (data not shown).
Although model selections were successful, we frequently encountered problems
leading to inconsistent results. For efficient product capture, AP-fused proteins should be
conjugated to the microbeads. The results of the biotinylation were, however, varied a lot with
1) the protein that is conjugated to beads (e.g. HP1-AP, AP-psBCCP (K--A) (where the lysine
biotinylation site of psBCCP (P shermanii transcarboxylase 1.3S subunit) was mutated to
alanine), or psBCCP), 2) the batch of commercial beads (which we cannot control), and 3)
storage conditions. We also observed that proteins conjugated to the beads were degraded over
time. Throughout the protein evolution by IVC, this inconsistency limits the selection process.
In addition, although the gene was triply biotinylated to ensure their binding to beads through
the process, DNA recovery after selection was sometimes difficult probably due to
dissociation of biotinylated gene from streptavidin-coated beads. Unfortunately, our numerous
attempts to improve the reproducibility, such as preparing larger batches of microbeads at one
time, were not successful. We assumed that microbeads are the reason for inconsistency
problems, and decided to design a new IVC platform without microbeads.
BirA evolution strategy: bead-less IVC
In the bead-less IVC strategy, an AP peptide is covalently linked to DNA as shown in
Figure 3. The droplet size can be smaller than that of bead-based IVC due to lack of beads,
which allows us to input a larger library. Moreover, we can employ an affinity based product
capture scheme and avoid a fluorescence-based assay which requires time-consuming flow
cytometry.
AP peptide-oligonucleotide conjugates were prepared through aldoxime formation
between commercially available 5'-aldehyde modified oligonucleotides and AP peptide with a
hydroxylamine group on its N-terminus, followed by reduction with sodium cyanoborohydride.
The AP conjugated oligonucleotides are then purified by preparative HPLC (see appendix for
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Figure 3 Selection scheme for bead-less IVC. In step 1, AP peptides were covalently
attached to both ends of BirA mutant genes, and the peptide-DNA conjugates were
mixed with IVTM and segregated in individual aqueous compartments within a
water-in-oil emulsion. Within the compartments the BirA mutants are expressed from
the gene (step 2). Active mutants (left) biotinylate the AP peptides on the genes,
whereas inactive mutants (right) do not. After breaking emulsions, the aqueous
solution was incubated with streptavidin beads, which binds to the biotin on the
genes (step 3). The beads were washed and spun down. The genes were recovered
from the beads through PCR for input into the next round of selection (step 4).
HPLC and MALDI-TOF data of the purified AP conjugated oligonucleotides). We observed
efficient biotinylation of the conjugated AP by BirA even in the presence of the
oligonucleotide (data not shown). To carry out the model selection with BirA and folA (a
negative control enzyme without biotinylation activity), genes for each were amplified by
PCR with these AP-modified primers and mixed in a ratio of 1:10 (BirA:folA). This resulting
solution was emulsified in mineral oil with IVTM to perform IVC. Biotinylated AP-DNA
pre selection post selection
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Figure 4 Results of bead-less IVC model selection using BirA and folA. folA is E.
coli dihydrofolate reductase, a negative control enzyme that lacks biotinylation
activity. Genes from before (pre) and after (post) the selection were PCR amplified
and analyzed by agarose gel electrophoresis. Selections were performed with BirA
only, folA only, and a 1:10 mixture of BirA:folA. It can be seen that the 1:10 mixture
becomes enriched in BirA after the selection.
conjugates were captured by streptavidin beads and amplified by PCR reaction (Figures 3 and
4). Consistent enrichment of BirA genes by 25-fold was observed. The enrichment factor is
lower than that of bead-based IVC for several reasons. We observed high background
biotinylation due to endogenous BirA in E. coli lysates of the IVTM. The bead-based platform
was less affected by background biotinylation due to the large number of substrates in a
compartment. Although it is slightly improved by shorter incubation time, even the small
amount of endogenous BirA could biotinylate AP-DNA conjugates under our single-turnover
condition, which utilizes only two substrates in one droplet. Also, non-specific binding of
DNAs to streptavidin beads decreased the selection efficiency although it could be minimized
by pre-blocking of streptavidin beads with Calf thymus DNA.
Model selection with wild type BirA and kinetically impaired G115S BirA.
Bead-less IVC is a two-turnover selection system by its design, which is a
disadvantage compared to bead-based IVC, which presents many copies of AP within each
droplet. A two-turnover system has less likelihood to enrich highly active catalysts over
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Figure 5 Bead-less IVC model selections using wild type (WT) BirA and kinetically-
impaired G115S mutant. G115S BirA shows slower biotinylation compared to WT
BirA due to its greater rate of dissociation (kff) for biotin (WT BirA: 0.33 (±0.01) s-',
G115S: 80 (±20) S~1)29. (A) The horizontal line in the scheme represents DNA. In
compartments expressing a fast BirA mutant, such as WT BirA, we expect a high
level of biotinylation of both free and bound AP peptide. In compartments expressing
a slow BirA mutant, such as G1 15S, we expect a low degree of biotinylation of free
and bound AP peptide. Streptavidin beads are used to selectively pull down genes
encoding fast BirA mutants. K3AP is an AP peptide with 3 additional N-terminal
lysines to improve solubility. (B) IHPLC analysis of K3AP biotinylation by WT BirA
and G115S. K3AP peptide was reacted with WT BirA (red) or G115S mutant (blue)
and analyzed by HPLC. Reaction condition: 1 pM enzyme (WT or G115S BirA), 1
mM biotin, 100 IM K3AP, 4 mM ATP, 5 mM magnesium acetate, 5 min, 30 *C.
Reactions were analyzed by C18 reverse-phase HPLC using a gradient of 10 - 43%
acetonitrile in water with 0.1% TFA over 40 min (flow rate 1 mL/min).
Chromatograms were recorded at 210 nm.
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Figure 6 Results of model selections with wild type (WT) BirA and G115S using
bead-less IVC. Genes from before (pre) and after (post) the selection were PCR
amplified and analyzed by agarose gel electrophoresis. Selections were performed
with a 1:10 mixture of WT BirA: folA (lane 1), or a 1:10 mixture of WT BirA:
G115S (lanes 2 and 3). The difference between lane 2 and 3 is the incubation time
with IVTM (3 h for lane 2 and 6 h for lane 3). BirA and folA mixture in lane 1 was
incubated with IVTM for 6 h. No enrichment of G115S over WT BirA was observed.
moderately active ones, compared to a multiple-turnover based selection system.
We attempted to introduce multiple-turnover selection to bead-less IVC by adding
excess free AP peptide as shown in Figure 5A. In order to improve solubility, K3AP, an AP
peptide with three additional N-terminal lysines was added instead of AP. Enzyme expressed
in a compartment will more likely use free substrates (-6000 molecules) than immobilized
ones on the gene (only two AP's per gene). Concentration of the added K3AP substrates was
equal to the KM value of AP toward BirA (-25 pM30). This method was tested by a model
selection between wild type BirA and BirA G1 15S mutant. Gly 115 is located in a disordered
loop of BirA that becomes ordered upon biotin binding, and alteration within the loop affects
in enzymatic activity," 3 2 . BirA G115S mutant shows a -200-fold greater rate of dissociation
(kog) for biotin than wild type BirA (wild type BirA: 0.33 (±0.01) s-, G115S: 80 (+20) s4)29
and thus we observed reduced biotinylation with BirA G115S compared to wild type BirA
(68% vs <1% conversion, Figure 5B) using 1 pM enzyme for 5 min at 30 'C. When
performing model selections with excess K3AP peptides, however, enrichment of wild type
BirA was not observed (Figure 6, lane 3). On the other hand, under identical conditions (with
excess free K3AP added), BirA was enriched over folA (Figure 6, lane 1). It is possible that
under the conditions of the selection, GI 15S BirA activity was high enough to biotinylate both
free and bound AP, leading to a lack of enrichment over wild type BirA. Addition of more free
K3AP peptides than -6000 molecules / compartment was restricted by the low efficiency of
free K3AP peptide removal and by limited binding capacity of streptavidin beads. We also
tried to shorten the reaction time (Figure 6, lane 2), but it did not give any enrichment as well.
While our goal is to improve the catalytic efficiency of BirA against the AP peptide,
the single-turnover nature of bead-less IVC did not allow us to discriminate kinetically
between enzymes. However, our IVC selection could potentially still be a useful tool to find a
BirA mutant that accepts unnatural biotin analog probes.
Conclusions
Re-engineering of BirA was attempted by in vitro compartmentalization (IVC), which
was originally performed using microbeads. We have invented a novel bead-less IVC selection
to solve the inconsistency problems of bead-based IVC and observed much more reproducible
selections. Several model selections were successfully performed, and the single-turnover
characteristic of current selection was analyzed. In parallel, a BirA mutant library for in vitro
evolution was prepared and characterized.
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Although many technical problems of bead-based IVC were solved by inventing
bead-less IVC, intrinsic problems of IVC have been clearly noticed. The use of IVTM allows
the production of proteins that are toxic to cells. However, the present bead-less IVC,
particularly for biotin ligase evolution, was limited by background biotinylation by
endogenous BirA in E. coli IVTM. This can be resolved by using eukaryotic systems such as
wheat germ extracts 33 or rabbit reticulocyte lysates3 4 . Unfortunately, these in vitro
transcription and translation systems are expensive and hard to maintain in house. They are
also very sensitive to temperature, and thus when homogenized at high speeds, the generated
proteins show loss of their activity'3 . The other drawback of IVTM includes its stickiness.
After breaking emulsions, we have purified the genes using size exclusion chromatography.
Even though we have repeated washing for three times, the residual IVTM still caused non-
specific sticking of DNAs to streptavidin beads, decreasing the enrichment factor of the
selection.
Moreover, our knowledge on in vitro expression of BirA is still limited. We do not
know how long it will take and how many molecules of BirA are expressed in each
compartment during the given amount of time. With this information, it would be much easier
to design a selection condition that can discriminate faster BirA mutants from others.
Emulsions are created by homogenization, and the size of each compartment varies
according to Gaussian-distribution' 3 . Therefore, some compartments will have different
number of genes or substrates, and this introduces a random bias in the selection. Recently,
35Weitz and coworkers employed microfluidic devices to create droplets with a uniform size .
Although they did not apply the technology to evolve an enzyme yet, it will allow them to
perform selections under almost identical conditions while preserving the quality of IVTM.
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The use of PCR to amplify the resulting clones from each round also limits the IVC
method. We had to perform at least 52 cycles of PCR to get enough DNA for next rounds in
bead-based or bead-less IVC. Such high numbers of PCR cycles sometimes generate chimeric
fragments by homologous recombination, and resulting shorter DNA fragments are more
readily amplified by PCR than original templates, producing false DNA product36 . In order to
solve the problem in part, Griffiths and coworkers developed emulsion PCR, where each gene
is compartmentalized with PCR reaction mixture3. They observed narrow distribution of the
PCR product size when PCR reactions were emulsified.
In order to evolve faster BirA using IVC, the selection should be under multiple-
turnover condition. Although bead-based IVC offers multiple turnover selection, microbeads
caused most of inconsistency problems of the method. Replacing microbeads with other solid
support such as yeast cells might improve the consistency of IVC. Yeast cells displaying AP
peptides were proven as efficient substrates for BirA (Chapter 2). By emulsifying each gene
encoding a mutant of BirA and yeast cell(s) displaying multiple AP peptides, we will be able
to achieve multiple-turnover selection. These emulsions can then be re-emulsified to generate
water/oil/water double emulsions, which can be sorted using FACS. Genes in the sorted
compartments will be amplified by emulsion PCR.
Experimental
Cloning of a partially-randomized BirA library by overlap extension PCR. The library
was synthesized from five randomized BirA gene fragments 1 - 5 using overlap extension PCR
(Figure 7). In a typical overlap extension PCR reaction, 1.7 nM of each fragment were mixed
in the presence of Roche Expand High FidelityPLUS PCR System and the reactions were cycled
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10 times (94 *C 0.5 min, 50 *C 0.5 min, 72 'C 3 min) without primers. Then a pair of flanking
primers was added, and the reactions were cycled 15 more times. Fragment 1 was amplified
from the pIVEX BirA template using the primers LMB2-1 (5'- CAG GCG CCA TTC GCC
ATT) and the rvT90 (5'- GTC AAT CAC TGG CAG CAC G), using 30 reaction cycles as
described above. Fragment 2 was similarly amplified using the primers fwT90 (TGC TGC
CAG TGA TTG ACT CCN NKA ATC AGT ACC TTC TT, where N= A, Q C, or T and K=G
or T; randomizes Thr 90) and rvQ 112 (5'- CTG CTG GTA TTC TGC AAT G). Fragment 3
was similarly amplified with the primers fwQ 112 (5'- GAT GCT TGC ATT GCA GAA TAC
NNK CAG GCT NNK CGT GGT CGC CGG GGT CGG AAA NNK TTT TCG CCT TTT
GG; randomizes Gln 112, Gly 115, and Trp 123) and rvG186 (5'- TGC CAG CTT GCG ATC
CTG). Fragment 4 was similarly amplified with the primers fwG186 (5'- CAG GAT CGC
AAG CTG GCA NNK ATT CTG GTG GAG C, where N= A, Q C, or T and K=G or T;
randomizes Gly 186) and rvG204 (5'-AAT GAC TAT TTG CGC CGC AT). Fragment 5 was
similarly amplified with the primers fwG204toG206 (5'-ATG CGG CGC AAA TAG TCA
TTN NKN NKN NKA TCA ACA TGG CAA TG; randomizes Gly 204, Ala 205, and Gly 206)
and PIVB1 (5'- GCG TTG ATG CAA TTT CT). Finally, the entire fragment (1+2+3+4+5) was
PCR amplified with triply biotinylated primers LMB2-1 and PIVB 1.
1 2 3 4 5
T90 Q112 G186 G204
G115 A205
W123 G206
Figure 7 The BirA library was created using overlap extension PCR. Five fragments
1 - 5 of gene were shown. Each end of the gene was biotinylated for immobilization
on streptavidin-coated beads.
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Synthesis of microbeads functionalized with HP1-AP, psBCCP, or AP-psBCCP (K-*A)
Cloning and bacterial expression of HP1-AP, psBCCP, and AP-psBCCP (K-A). The
pET-23d plasmid for bacterial expression of P shermanii transcarboxylase 1.3S subunit
(psBCCP) was a kind gift from A.D. Griffiths and B. T. Kelly (MRC Laboratory of Molecular
Biology, UK). Others in the lab constructed the pET21 plasmid for bacterial expression of
HP 1 -AP by standard PCR subcloning techniques.
In order to clone AP-psBCCP (K-*A), site-directed mutagenesis on the lysine
biotinylation site of psBCCP was performed with psBCCP (K/A).F (5'-GCT CGT TCT CGA
GGC CAT GGC GAT GGA GAC CGA GAT CCA AC) and psBCCP (K/A).R (5'-GTT GGA
TCT CGG TCT CCA TCG CCA TGG CCT CGA GAA CGA GC) using QuikChange system
(Stratagene). Two successive PCR reactions were performed to construct an insert containing a
HA tag, AP, and psBCCP. For the first PCR, the psBCCP (K-*A) gene was used as the
template, and the primers HAAPfwl (5'-GCC TCA ATG ACA TCT TCG AAG CCC AGA
AAA TCG AAT GGC ACG AAA TGA AAC TGA AGG TAA CAG TCA ACG GCA C;
incorporates AP sequence) and HAAPrvl (5'-TCG ATG AGC TCG AGA TCC CCG ATC
TTG ATG AGA CCC TGA C; incorporates a SacI site) were used for the amplification. For
the second PCR, the product of the first PCR reaction was used as the template and the
primers HAAPfW2 (5'- TTC ATG GGA TCC TAC CCC TAC GAC GTC CCC GAC TAC
GCC GGC GGC TCC GGC GGC CTC AAT GAC ATC TTC GAA GCC; incorporates the HA
sequence and a BamHI site) and HAAPrvl were used for the amplification. The insert was
digested with BamHI and SacI and ligated in-frame to similarly digested pET-23d vector
(Novagen), which introduces a C-terminal His6 tag.
The pET-23d plasmid containing the psBCCP or AP-psBCCP gene and the pET-21b
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plasmid containing the HP 1 -AP gene were introduced into E. coli strain BL21 (DE3) by heat-
shock transformation. The cells were cultured in LB supplemented with ampicillin (100
tg/mL) at 37 'C until OD 600 0.5. Protein expression was induced by the addition of IPTG to a
final concentration of 0.4 mM. After incubation at 30 'C for 3 h, the cells were harvested by
centrifugation. The cells were lysed by sonication at 4 'C (three 10-second pulses at half-
maximal power with 1 min between each pulse) in lysis buffer (50 mM Tris pH 7.8, 300 mM
NaCl) containing 0.5 mM phenylmethylsulfonyl fluoride (PMSF), protease inhibitor cocktail
(Calbiochem), and DNase I (Roche). After incubation at room temperature for 20 min, the
lysate was cleared by centrifugation, and the supernatant was loaded onto a Ni-NTA agarose
column (Qiagen). Fractions containing the desired proteins (psBCCP, AP-psBCCP (K->A) or
HP1-AP) were consolidated and dialyzed against PBS pH 7.4 overnight. The concentration of
protein was determined by BCA assay. Removal of biotinylated proteins was performed with
streptavidin-agarose beads as described elsewhere. The cysteine residue on HP1-AP was
capped by incubating with 4 mM N-ethylmaleimide for 30 min at room temperature, and
excess N-ethylmaleimide was removed by dialysis.
Synthesis of thiol-modified beads (modified from Irwin Chen and Dr. Baruah's protocol)
Microbeads were vortexed before use. A total of 25 pL of carboxylate-modified microbeads
(10% suspension, -4 x 109 beads, Bangs laboratories) were washed (resuspended in buffer and
pelleted by centrifugation (13,200 rpm, 2 min, 20 C)) with PBS-T (phosphate-buffered saline
+0.1% Tween) once. The beads were then pelleted and washed once with 500 tL of MES
buffer (50 mM 2-(N-morpholino)ethanesulfonic acid pH 6.2) and resuspended in 400 jiL MES
buffer. To the bead suspension was added sulfo-N-hydroxysuccinimide to a final concentration
of 100 mM and then 1-ethyl-3-(3-dimenthylaminopropyl) carbodiimide hydrochloride (EDC)
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to a final concentration of 100 mM in MES buffer. The pH of the reaction was maintained at
6.2. The beads were agitated for 20 min at room temperature and then washed twice with 500
ptL MES buffer. The beads were resuspended in 200 pL of a solution of 1 mM cystamine in
bicarbonate buffer (0.1 M NaHCO3 pH 8.2, prepared every time before use) and agitated for
2.5 h. The beads were washed twice with 500 pL PBS-T, resuspended in 500 pL of PBS
containing 20 mM dithiothretiol (DTT), and then agitated at room temperature for 1.5 h. The
beads were washed three times with 500 pL PBS-T prior to conjugation to protein.
Synthesis of protein-SMCC conjugates (modified from Irwin Chen and Dr. Baruah's
protocol) In the meantime, both streptavidin (either prepared in house or purchased from New
England Biolabs) and the protein substrate were reacted with succinimidyl 4-[N-
maleimidomethyl]cyclohexane-1-carboxylate (SMCC). To make psBCCP-functionalized
beads, SMCC was added to 50 pL of psBCCP solution (20 mg/mL in PBS) and 50 piL of
streptavidin solution (1.5 mg/mL in PBS) to final concentrations of 4.8 mg/mL and 0.7 mg/mL,
respectively. The reactions were incubated at room temperature for 45 min and the protein-
SMCC conjugates were purified from excess SMCC using size exclusion chromatography on
a NAP-5 (SephadexTM G-25 resin, GE Healthcare) column. The proteins were eluted from
the column in 1Ox100 tL fractions in PBS supplemented with 1 mM EDTA. The four most
concentrated fractions of psBCCP-SMCC conjugate were combined with the two most
concentrated fractions of streptavidin-SMCC.
To make HP1-AP-functionalized beads, SMCC was added to 120 pL of HP1-AP
solution (1.0 mg/mL in PBS) and 50 pL of streptavidin (1.5 mg/mL in PBS) to final
concentrations of 0.2 mg/mL and 0.3 mg/mL, respectively. Following 45 min, the reactions
were purified on a NAP-5 column as described above for psBCCP. The HP1-AP and
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streptavidin-SMCC conjugates were mixed as described above for psBCCP.
Conjugation of protein-SMCC to thiol-functionalized beads The thiol-functionalized beads
synthesized above were resuspended (by sonication) in the streptavidin-protein substrate of
BirA-SMCC mixtures and agitated at room temperature overnight. The beads were washed
three times with 500 ptL of PBS-T and resuspended in 225 ptL of PBS-T to make a 1%
suspension, assuming a 90% recovery of the beads. This corresponds to 1.6 x 107 beads/ pL,
or a concentration of 27 pM.
Model selection of BirA and folA using bead-based IVC (modified from B. Kelly's
protocol for use in Ting Lab).
Emulsification of microbeads. A total of 1.28 x 108 beads were pre-blocked in 40 pL PBS-T
containing 8 mg/mL heparin for 1 h. The beads were washed twice with PBS-T, resuspended
in a solution of biotinylated BirA DNA in 40 tL PBS-T, and agitated for 30 min. In typical
experiments, the DNA was bound to the beads in a 1:3 ratio (DNA/bead). For model selections,
BirA gene and folA gene (dihydrofolate reductase (DHFR) gene) were amplified from pIVEX
plasmids harboring BirA and folA genes (a kind gift from A.D. Griffiths and B. T. Kelly) with
5'-biotinylated primers. The biotinylated BirA and folA genes were mixed in 1:10, 1:100, and
1: 1000 ratios (BirA/folA). The beads were washed twice with TA buffer (5 mM Tris-acetate
pH 8.0), resuspended by sonication in 20 pL TA, and chilled on ice. To the bead suspension
was added 33 pL of chilled 1x IVTM from the RTS 100 E. coli HY Kit (Roche), additionally
supplemented with 23 pM of biotin. 50 pL of the resulting well-mixed bead suspension was
then added to a 2 mL Nunc CryoTube vial containing 500 pL of chilled mineral oil (Sigma)
with 4.5% w/w Span-80 and 0.5% w/w Triton-X-100. The water-in-oil emulsions were formed
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by stirring on ice at 1100 rpm for 3 min and homogenizing further on ice at 11,000 rpm for 3
min using an IKA Labortechnik Ultra-Turrax T8 homogenizer. The emulsions were then
incubated at 30 'C for at least 8 h.
Breaking the emulsion. The emulsion was transferred to a 1.5 mL eppendorf tube and
centrifuged (13,200 rpm, 15 min, 15 'C). The less dense oil phase was removed and the
remaining emulsion was broken by three extractions with 1 mL mineral oil. One round of
extraction involves resuspension of the emulsion in oil, centrifugation (13,200 rpm, 10 min,
15 C), and removal of the oil phase. After the emulsion was broken to reveal two distinct
phases, an oil phase on top and an aqueous phase containing the bead pellet, both layers were
removed carefully, and the pellet was resuspended in 100 p.L of PEET buffer (PBS-T
supplemented with 5 mM ethylenediamine tetraacetic acid (EDTA) and 5 mM ethylene glycol
tetraacetic acid (EGTA)). One mL of mineral oil was added; the mixture was vortexed; the
beads were pelleted by centrifugation (13,200 rpm, 3 min, 15 0C); and both phases were
removed from the pellet. The beads were resuspended in 100 pL of PEET, and residual oil was
removed from the aqueous layer by three extractions with 1 mL hexane. The remaining hexane
in the aqueous layer was evaporated by heating at 30 0C for 15 min. The beads were pelleted
and washed twice with wash buffer (10 mM Tris pH 7.4 with 1 mM EDTA and 2 M NaCl).
Streptavidin-PE staining for biotinylated beads. The beads were stained with streptavidin-
PE (1:100 dilution in 0.5x wash buffer, Jackson ImmunoResearch) for 1 h. The beads were
washed three times with PBS-T, and resuspended in 500 pL PBS-T for flow cytometry
(FACScan, BD Biosciences) or bead sorting.
DNA recovery from the beads. Following a sort, the collected beads were pelleted by
centrifugation (13,200 rpm, 10 min, 20 'C) and washed twice in 1x PCR buffer and
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resuspended in 25 pL of PCR buffer. The beads were input into 100 pL PCR reactions with the
primers LMB2-7 (5'-AAG TTG GGT AAC GCC AGG) and PIVB-7 (5'-TAC GCG ATC ATG
GCG AC), and the reactions were cycled 22 times (94 'C 0.5 min, 50 'C 0.5 min, 72 'C 2
min) before holding at 72 'C for 7 min. Then, 1 pL of this PCR reaction served as the template
for the next PCR reaction with nesting primers (30 cycles like above).
Bead-less IVC
Conjugation of AP peptide and primers. Two aldehyde modified custom primers ALD-
LMB2-3 (GGA AGG GCG ATC GGT GCG) and ALD-PIVB3 (GAG CAC TGT CCG ACC
GC) were purchased from Invitrogen. We made 100 pM stock solutions of these primers in
water. The conjugation reaction with 50 pM of primers, 10 mM NaOAc pH 4.5, and 1 mM
AP-hydroxylamine (hydroxylamine on N-terminus, custom synthesized from Tufts University
Core Facility, used as 10 mM stock solution in water and minimal sodium phosphate pH 8)
was incubated at room temperature for 6 h. Sodium cyanoborohydride was then added to 50
mM of final concentration, and the reaction was further incubated at room temperature for 3 h.
The reaction was purified by C18 reverse-phase HPLC using a gradient of 3 - 60% acetonitrile
in 50 mM ammonium acetate pH 7 over 30 min (flow rate 1 mL/min). Chromatogram was
recorded at 260 nm. Intact oligonucleotides have retention times of 8.5 min, but after
conjugation to AP peptide, the retention time should be increased to ~13.5 min. After
purification, each primer was run on HPLC to estimate the purity of the conjugate (Figure 1 in
Appendix). The identity of conjugation product was confirmed by MALDI-TOF measurement
(Figure 2 in Appendix). For some reason, we have failed to get mass peaks corresponding to
AP conjugated PIVB3, even with desalted and concentrated samples. However, the retention
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time of AP conjugated PIVB3 (~13.5 min) was different from starting materials (AP-
hydroxylamine peptide: 16 min, ALD-PIVB3: 8.5 min). The mock conjugation control without
AP peptide also showed that the retention time of ALD-PIVB3 does not vary much after
reduction. Therefore, we assumed that the purified material from the conjugation reaction is
actually AP conjugated PIVB3.
AP conjugated genes (wild type BirA, folA, and G115S BirA) were prepared by PCR
reactions using these AP conjugated primers and the corresponding templates.
Preparation for making emulsions. 500 pL of mineral oil mix were put in a Nunc CyroTube
vial with an 8x2 mm stir bar, and the vial was placed on ice to chill the oil mixture. AP-
conjugated genes were prepared as a 3.3 nM solution in 10 mM Tris-acetate pH 8. This will
give a final concentration of DNA in the IVTM of 275 pM. Two falcon tubes containing water
and absolute ethanol separately were prepared to rinse the homogeneizer.
Making DNA/IVTM mixtures. In a 650 pL eppendorf tube, 22 pL of sterile water and 5 pL
of 3.3 nM stock solution of AP conjugated gene construct were mixed. For model selections,
DNA mixture was combined to achieve a final concentration of 275 pM in 60 L. To make
1:10, 1:100, and 1: 1000 dilutions (BirA: folA or WT: G115S BirA), serial dilutions of original
stock solution were made. For model selections with wild type BirA and G115S mutant, K3AP
was added to DNA mixture to a final concentration of 25 tM. The tube was then placed on ice.
IVTM mixture was generated on ice by combining 11.5 pL of lysate, 9.6 piL of reaction
mixture, 11.5 pL of amino acids, 0.98 pL of methionine, 5 ptL of reconstitution buffer, and 0.9
pL of 1mM biotin. Immediately prior to forming emulsions, 33 pL of IVTM was added to the
27 ptL of gene construct made as above. The reaction mixture was remained on ice before
homogenizing.
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Forming Emulsions. The tube containing the mineral oil mixture was placed on ice and put
on the stirrer at 1,150 rpm. 50 ptL of IVTM-DNA mixture were added to the stirring oil and
stirred further for 3 min. The oil became cloudy, and the tube was removed from the stirrer,
and the stir bar was also removed from the tube. The tip of the homogenizer was placed into
the tube and the mixture was homogenized at 25,300 rpm for 3 min. The homogenizer was
then put out, and the tube was capped and incubated at 30 'C for overnight. The homogenizer
was cleaned with one thorough wash with ethanol, followed by a thorough wash with water.
All traces of water in the final wash should be removed before next use.
Break Emulsions. 200 pL of PBS-T was added to emulsions and the mixture was transferred
to a clear 1.5 mL eppendorf tube. The mixture was then spun down at 15 'C with 13,000 rpm
for 10 min. We usually saw a pellet of emulsions at the bottom of the tube, then an aqueous
layer of quench buffer, and a top layer of mineral oil. The layer of mineral oil was removed. 1
mL of pure mineral oil (Sigma) was added to the tube and the pellet was re-suspended by
flicking with fingers. The tube was again spun down for 5 min at 15 'C with 13,000 rpm. The
top layer was removed again. Until no more pellet is observed and the solution is clear,
mineral oil was added and removed as above for three to four more times. Any white
interphase was removed. In order to remove residual mineral oil, 1 mL of hexane was added.
The mixture was resuspended and spun down for 1 min at 13,000 rpm. The hexane layer was
removed, and this hexane washing was repeated for two more times. Residual hexane was
evaporated off by air-drying for 10 min. The aqueous phase is then purified with size
exclusion column (G-25, Bio-Rad) to remove residual IVTM or excess K3AP peptide.
Binding to streptavidin beads. M-280 streptavidin-coated dynabeads (50 ptL) were washed
twice with 2X binding and washing buffer plus Triton X- 100 (BWT) buffer (10 mM Tris-HCl,
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pH 7.5/ 1 mM EDTA/ 2.0 M NaCI/ 0.1% vol/vol Triton X-100). The beads were then
resuspended in 2X BWT buffer. 180 ptL of IVTM reaction was added to the beads and the rest
20 ptL was saved for future PCR. The beads were then rotated at room temperature for 15 min
and washed with 200 tL of 2X BWT; 200 ptL of GHCl Buffer (3 M guanidinium
hydrochloride/ 25 mM sodium phosphate, pH 7.2/ 1mM EDTA); 200 pL of 2X BWT; 200 pL
of water. The beads were finally resuspended in 25 pL of water.
DNA recovery by PCR from beads. 10 pL of the beads above was added to a PCR reaction
solution on ice containing 10 pL of lOX Pfu buffer, 4 pL of mixture of dNTPs, 1 ptL of 100
pM primer 1 (PIVB-9; 5'- TAT CCG GAT ATA GTT CC), 1 pL of 1OOuM primer 2 (LMB2-9;
5'- GTA AAA CGA CGG CCA GT), 2 pL of Pfu-Turbo DNA polymerase, and 72 pL of sterile
water. PCR was performed for the following cycles: a) 94 'C 2 min, b) 94 'C 10 sec, c) 50 'C
30 sec, d) 72 'C 54 sec, e) repeat b) to d) 19 times, f) 72 'C for 7 min, g) 4 'C forever. 2 pL of
this PCR product was taken to the nested PCR reaction solution containing 10 pL of I OX Pfu
buffer, 4 pL of mixture of dNTPs, 1 pL of 100 pM primer 1 (sacI-outer-R; 5'- GCT TTG TTA
CCG GAT CCC GG), 1 pL of 100 pM primer 2 (PVX-rbs-ncol-F; 5'- TTA AGA AGG AGA
TAT ACC ATG G), 2 ptL of Pfu-Turbo DNA polymerase, and 72 pL of sterile water. PCR were
cycled under the same condition as above. PCR products were analyzed on an agarose gel.
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Chapter 4: Development of a Streptavidin Evolution Platform Based on In
Vitro Compartmentalization
This chapter describes our efforts to evolve streptavidin variants that bind a ketone
analog of biotin, using in vitro compartmentalization (IVC). My specific contributions were as
follows. The selection scheme and model selections with wild type and S45A streptavidin
(SA) were developed by Dr. Dan Chinnapen and Dr. Guobin Luo, post-doctoral fellows in the
Ting laboratory. I reproduced their model selection. I then prepared two streptavidin mutant
libraries and performed three rounds of selection with ketone biotin.
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Introduction
Biotin binding to streptavidin is one of the strongest non-covalent interactions (Kd-
10-13 M) found in Nature. By virtue of its unusual stability, the streptavidin-biotin pair has
been used in many fields from biochemistry to nanotechnology2 ,3 . The protein is a homo-
tetramer, and each subunit (~15 kDa) binds to one molecule of biotin. The crystal structure of
biotin-bound streptavidin showed that various types of interactions are simultaneously
involved to achieve the extremely high affinity of streptavidin to biotin. Four tryptophan
residues (Trp 79, Trp 92, Trp 108, and Trp 120) of the protein contribute the van der Waals
type interaction with biotin. Seven hydrogen bonding interactions further increase the affinity,
and an ureido-oxyanion resonance form of biotin is stabilized by the extended hydrogen
bonding network including Ser 45 and Asp 128 (Figure 1). These two residues particularly
play a crucial role in the affinity of the protein to biotin. When one of the two residues was
mutated to alanine, the protein affinity to biotin was decreased 1000-fold. Residues 45 to 52
also form an open binding loop in the apo form, which is closed after biotin binds.
Altering the extraordinary binding specificity of streptavidin toward biotin has been of
high interest since the development of a new streptavidin (streptavidin 2)-biotin analog (biotin
2) pair will extend the range of current streptavidin-biotin technology (Figure 2). Moreover, if
the newly developed streptavidin 2-biotin 2 pair is orthogonal to streptavidin-biotin pair,
meaning the streptavidin 2 does not bind to biotin with high affinity while still exhibiting great
affinity toward biotin 2, the pair could be used simultaneously with the streptavidin-biotin pair.
Since the binding site of streptavidin is highly optimized for biotin, any kind of mutations in
the area will cause a reduced affinity toward biotin4 . Cantor and coworkers have generated
streptavidin mutants to reduce the binding affinity to biotin while maintaining affinities to
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Figure 1 Crystal structure of the biotin binding site of streptavidin. The surface of
biotin is shown with the wire mesh. Residues close to biotin and the binding loop
(residues 45 to 52) are labeled.
biotin
biotin 2 ' streptavidin 2
Figure 2 A proposed orthogonal pair of streptavidin and biotin analogs. "Streptavidin
2" does not bind to biotin, and wild type streptavidin does not bind to "biotin 2"
(dotted arrows). However, streptavidin 2 binds to biotin 2 with high affinity (solid
arrows), like the wild type streptavidin-biotin interaction.
2-iminobiotin and diaminobiotin (Figure 3)5. In order to change the local electrostatic charge
distribution of the binding pocket, they created a N23A and S27D double mutant based on
molecular modeling and free energy calculations. They found that this mutant shows higher
affinity to 2-iminobiotin (Kd = 1 x 106 M) than to biotin (1 x 10 -4 M), although the affinity to
diaminobiotin (3.7 x 10~5 M) is lower than that to biotin (3.4 x 10- M). Although the affinity
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achieved is too weak for labeling applications, they showed that the ligand specificity of
streptavidin can be modified using de novo design. Dixon and coworkers also employed a
computational approach to find a biotin analog that binds streptavidin tighter than biotin. 9-R-
methylbiotin (Figure 3), which has a methyl group immediately before the carboxylic acid
group of the aliphatic tail, was observed to have 10-fold higher Kd value (10-fold weaker
interaction) than biotin to streptavidin .
Combinatorial approaches have been employed to change the ligand specificity as
well. Cantor and coworkers accidentally found a single-chain dimeric (SCD) streptavidin
mutant that exhibits a Kd of 10-10 M for biotin-4-fluorescein (B4F, Figure 3) whereas its Kd for
biotin is as low as 10-5 M7. Originally, their goal was to create a SCD streptavidin with as high
affinity to biotin as wild type. To achieve this, a phagemid library of SCD was created by a
trans-nitrogen O cis-nitrogen 0 NH
HN NH HN NH HN NH
H\ /4H H H Ht H
, OH OH OH
biotin desthiobiotin 2-iminobiotin
00
H2N NH 2  HN NH
HOH H . OH OH
O 0 0
diaminobiotin 9-R-methylbiotin ketone biotin
0
HN NH
H H H O
N OH
0 Hi
HO 2C 0
biotin-4-fluorescein (B4F)
Figure 3 Structure of biotin analogs that have been investigated for streptavidin
engineering.
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circular permutation of streptavidin gene followed by error-prone PCR. They explain that the
unexpected tight binding of B4F to the SCDs is due to the fluorescein moiety, complementing
Trp 120 of wild type streptavidin. In addition to searching for streptavidin mutants that bind
small molecules other than biotin, streptavidin has also been engineered to have a higher
affinity toward the Strep-tag II peptide, a small streptavidin binding peptide . Functional
streptavidin mutants from E. coli colonies were captured by anti-streptavidin antibody, and
their binding to Strep-tag II was assayed using alkaline phosphatase-fused Strep-tag II. After
incubated with chromogenic substrates, streptavidin mutants that bind the Strep-tag II could be
screened. At the outset of the project, however, directed evolution of streptavidin with
systematic binding assays was not reported.
As reviewed in Chapter 1 and Chapter 3, in vitro compartmentalization (IVC) has
been successfully used for directed evolution of enzymes. Selections for binding, however,
were mostly performed via panning in phage display. Usually, proteins were displayed on
phage, RNA, or DNA rather than on beads since beads are too heavy for the relatively weak
binding forces9 . Omitting the transformation step, IVC can be superior to other in vivo
selections (e.g. phage display) because a larger library can be produced. Various protein
binders were successfully engineered using bead-less IVC. For example, zinc finger proteins
binding specific DNA sequence with high affinity have been evolved from a background of a
related zinc finger protein mutants 0 . Variants from the SH3 domain of the Fyn kinase were
also generated using this technique to have nanomolar affinities to mouse serum albumin
(MSA)". More interestingly, novel p53 variants with altered response elements specificities
were evolved using IVC . In the study, the P75L mutant of p53 which is transactivation-
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deficient in yeast was selected using IVC, highlighting the advantage of in vitro selection
which is independent from cell-viability.
In the present chapter, our attempt to evolve an orthogonal biotin 2/ streptavidin 2 pair
using IVC will be discussed. We envisioned that ketone biotin (Figure 3)13 would be a good
candidate for biotin 2 since ketone biotin has a low binding affinity to streptavidin, most likely
due to the absence of the ureido nitrogens. Directed evolution of a streptavidin mutant which
binds to ketone biotin with very high affinity and specificity, while maintaining a low affinity
toward biotin, would be the ultimate goal of the project. Dr. Chinnapen and Dr. Luo in our lab
have developed and optimized an IVC protocol for streptavidin evolution against other biotin
2 candidates. Design and creation of streptavidin mutant libraries, selection with these libraries
for ketone biotin binding, and the analysis of affinities were performed independently.
Results and Discussion
In order to select streptavidin mutants that bind to a ketone analog of biotin, ketone
biotin was covalently linked to DNA encoding streptavidin mutants as shown in Figure 4. In
the microdroplet, streptavidin mutants are transcribed and translated in vitro as in IVC for
BirA. If a streptavidin mutant binds to ketone biotin with a high affinity, the binding will be
maintained through the process of breaking emulsions and washing steps. Since streptavidin
mutants have His6 tags by design, pulling down with Ni-NTA beads will separate the genes of
mutants with high affinities from those of mutants with low affinities. Thus, PCR
amplification of the DNA from Ni-NTA beads will provide the genes for high affinity mutants
selectively.
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* Ketone biotin
(KB, see Figure 3 for structure)
1. Emulsify with in vitro transcription and
translation mixture (IVTM)
low affinity mutant high affinity mutant
KB -conjugated streptavidin library
4. Wash and PCR
from Ni-NTA agarose
2. In vitro transcription and translation within compartments
NINTA
3. Binding to Ni-NTA agarose
Figure 4 Proposed bead-less IVC selection scheme for streptavidin mutants that bind
to ketone biotin". In step 1, a ketone biotin (blue)-conjugated streptavidin gene
library is mixed with IVTM and segregated in individual aqueous compartments
within a water-in-oil emulsion. Within the compartments the streptavidin mutants are
expressed from the gene (step 2). Mutants with high affinities to ketone biotin (right,
pink) bind to the ketone biotin at the ends of DNA, whereas mutants with low
affinities to ketone biotin (left, grey) do not bind to the DNA. After breaking
emulsions, the aqueous solution is incubated with Ni-NTA agarose, which binds to
the His6 tag of each streptavidin molecule (step 3). The Ni-NTA beads are washed
and the genes are recovered from the beads through PCR for input into the next round
of selection (step 4).
After we started the project, Levy and Ellington reported that streptavidin mutants
were evolved to have high affinities toward desthiobiotin (Kd = -10- M) using the exactly
same selection scheme as our IVC selection14 . They used real time PCR reactions (RT-PCR) to
estimate the amount of bound streptavidin mutant genes from each round. Here, however,
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desthiobiotin cannot be used as an orthogonal biotin 2. Compared to ketone biotin which binds
to streptavidin about 107-fold weaker than biotin, desthiobiotin already strongly interacts with
streptavidin (only 100-fold weaker than biotin').
Model selection with wild type (WT) and S45A streptavidin (developed by Dr. Chinnapen
and Dr. Luo; I reproduced their selection as shown in Figure 6)
0 biotin 1. Emulsify with in vitro transcription andtranslation mixture (IVTM)
S45A Wild type (VVT)
biotin-conjugated wild-type and
S45A streptavidin genes
4. Wash and PCR oil waterfrom Ni-NTA agarose
2. In vitro transcription and translation within compartments
Ni -NTA
NI-NTA
3. Binding to Ni-NTA agarose
Figure 5 IVC model selection scheme with wild type (WT) and S45A streptavidin.
In step 1, a biotin (red)-conjugated WT and S45A streptavidin (50 bp longer than
WT by design) genes are mixed with IVTM and segregated in individual aqueous
compartments within a water-in-oil emulsion. Within the compartments the
streptavidin mutants are expressed from the gene (step 2). WT streptavidin (right,
green) binds to the biotin at the ends of DNA very tightly, whereas S45A
streptavidin (left, white) binds to the DNA more weakly. After breaking emulsions,
the aqueous solution is incubated with Ni-NTA agarose, which binds to the His6 tag
of WT and S45A mutant (step 3). The Ni-NTA beads are washed and the genes are
recovered from the beads through PCR and analyzed on an agarose gel (step 4).
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selection 1000 bp
S45A 850 bp650 bp
VV 500 bp
selection
S45A
VWT
A10 A A A
0 00000090
1:10. 1:100. or 1:500: starting WT: S45A ratio
12 h or 18 h : competition time with free biotin
Figure 6 Results of model selections with wild type (WT) and S45A streptavidin. (A)
The genes were mixed in 1:10 and 1:500 ratios (WT: S45A). IVTM reactions were
incubated at room temperature for 3 h, followed by competition with excess biotin at
37 *C for 11 h. pre: before selection, post: after selection. When WT and S45A were
mixed in a 1:10 ratio, WT was enriched over S45A after selection (-30-fold). (B)
Model selections with different lengths of competition time were performed. The
enrichment factor was higher (-100-fold) when the competition with free biotin was
performed longer (18 h). pre: before selection, post: after selection. S45A mutant
gene is 50 bp longer than that of WT by design.
Model selection of WT genes from S45A mutant genes of streptavidin was performed
to test the validity of the evolution method. As reviewed above, S45A mutant of streptavidin
exhibits a 1000-fold higher Kd (1000-fold weaker binding) than that of WT. Extra 50 DNA
base pairs were introduced to S45A mutant gene so that we can distinguish WT and S45A after
PCR amplification. The genes were then amplified by PCR with biotinylated primers and
mixed in a ratio of 1:10, 1:100, or 1: 500 (WT: S45A). This resulting solution was emulsified
in mineral oil with IVTM to perform IVC. Streptavidin mutants were then captured by Ni-
NTA beads, and the attached mutant genes were amplified by PCR reaction (Figure 5). Since
S45A mutant also binds to biotin with picomolar Kd, a competitive elution of the genes from
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the beads was performed by incubation with excess biotin at 37 'C. This exploits the faster
off-rate of the mutant, which has a half-life of 14 s at 37 'C, compared to that of WT
streptavidin which is much longer (6.6 h)". We observed higher enrichment of WT over S45A
mutant (up to 100-fold) when competition got longer (Figure 6). However, the enrichment was
low when the competition went too long such as for 24 h, probably due to the dissociation of
WT. Obtained enrichment factor in this model selection is significant considering that the
difference in Kd is 1000-fold, which is only 10-fold higher than the enrichment factor.
Design and construction of a streptavidin mutant library 1
Prior to implementing a selection to evolve a streptavidin mutant that binds ketone
biotin with a high affinity, a library of focused streptavidin mutants must be carefully designed
and constructed. Based on the crystal structure of streptavidin in complex with biotin, we
selected nine positions (Q24, S45, V47, W79, T90, W92, W108, LI10, and D128; Figure 7)
lining the binding pocket and close to a bound biotin. Two different libraries were generated,
namely cis and trans libraries, and mixed in a 1:1 ratio for selection. For the cis library, Ser 45
and Val 47 were chosen due to their hydrogen bond interaction with the cis nitrogen of biotin
(Figure 3). For the trans library, Gln 24 and Asp 128 were chosen due to their involvement in
the hydrogen bonding to the trans nitrogen of biotin. The rest of the randomized residues were
common for the two libraries and responsible for binding the lower thiolane ring of biotin. Thr
90 interacts with the sulfur group, and Trp 79, Trp 92, Trp 108 and Leu 110 play crucial roles
in forming the hydrophobic binding pocket. We have chosen these residues in the lower
binding pocket to compensate for any changes in the binding mode of ketone biotin compared
with that of biotin. Theoretical amino acid diversity of the library is 207 = 1 09.
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Figure 7 Randomized positions in streptavidin mutant library 1
Q24 S45 V47 W79 T90 W92 W108 L110 D128
Rd 0-1 Asn Ala Glu Val Trp Thr Pro Cys Asp
Rd 0-2 Asn Val Arg Gly Arg Glu Thr Thr Asn
Rd 0-3 Lys Ser Val Leu Ser Ser Leu Tyr His
Rd 0-4 Thr Ser Val Glu Ala Asn Ala Glu Lys
Rd 0-5 Gly Ser Val Val lie Trp Val Tyr Asp
Table 1 Sequences of random clones from streptavidin mutant library 1
We constructed the DNA library by PCR overlap extension. Synthetic oligonucleotides,
overlapping with the region of interest, contained NNK (N = A, T, Q or C; K = T or G)16
codons at the positions of saturated mutagenesis. The use of the K in the third position
excludes two out of three stop codons. After construction of the library, we checked the library
by sequencing five clones at random (Table 1). All nine amino acids were highly mutated and
we did not observe any contamination by the wild type streptavidin gene.
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Selection with the library (1)
The dissociation constant of streptavidin-ketone biotin binding was measured through
collaboration with Kulomaa's lab (University of Tampere, Finland). Isothermal titration
calorimetry was used to get a Kd value of 8.85 x 10-7 M for ketone biotin-streptavidin
interaction, which is 107 times weaker than biotin binding to streptavidin. The difference in the
binding affinity is the same as for S45A and D128A double mutants (Kd =1.22 x 10-6 M) 7 ,
suggesting that the library should be focused on the residues involved in the hydrogen bonding
with two ureido nitrogens.
An N-hydroxysuccinimide ester of ketone biotin was synthesized in situ and
conjugated to DNA oligonucleotides with amine-modified 5' ends. The conjugate was purified
by reverse-phase HPLC, and its mass was confirmed by MALDI-TOF measurement (See the
experimental section and appendix for characterization data). Finally, the streptavidin library
was PCR amplified with these primers.
For the first three rounds of selection, the in vitro transcription and translation mixture
(IVTM) was incubated for 3 h. No competition was performed to include the mutants with
very weak affinities to ketone biotin. Sequence analysis of clones from the rounds showed that
the trans library was slightly more dominant than the cis library, but it should be confirmed if
the selection is directed toward ketone biotin binding mutants as desired.
Functional assay: model selection with BirA
In early rounds of selection, the affinities of selected mutants toward ketone biotin
will be very low and therefore hard to determine. Currently available methods for measuring
the binding affinity provide reliable results only for those interactions with Kd in a micromolar
range or stronger, and in most cases a large amount of protein samples must be prepared.
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Therefore, it was hard to see if the binding affinity was increasing over the rounds in the early
stages of the selection by these traditional binding assays.
Instead, we performed model selections with the genes from each round against the
BirA gene because BirA does not bind ketone biotin with a high affinity (Km of ketone biotin
will be lower than that of biotin toward BirA, which is in micromolar range). The BirA gene
was PCR amplified also with ketone biotin conjugated primers. The selected streptavidin
mutant genes from each round (round 0 which is before selection, round 1 and 2) and BirA
genes were mixed in a 1: 10 ratio (streptavidin mutants from each round: BirA). IVC selection
was performed with these gene mixtures (as depicted in Figure 4) to examine whether
screened streptavidin mutants have higher ketone biotin binding affinities than BirA, thereby
streptavidin mutant genes are enriched from the BirA gene. After pulling down with Ni-NTA
beads, the genes were PCR amplified and analyzed on an agarose gel. As shown in Figure 8,
we observed slight enrichment of the streptavidin mutant genes from round 1 over the BirA
gene. This data indirectly indicates that selected streptavidin mutants from round 1 selection
might possess higher binding affinities to ketone biotin than BirA. However, the genes
amplified from the round 2 were shorter in length, probably due to the PCR-related artifacts.
As briefly discussed in Chapter 3, high numbers of PCR cycles (50 cycles here) with small
amount of template DNA sometimes generate chimeric fragments by homologous
recombination, and resulting shorter DNA fragments are more readily amplified by PCR than
original templates. In general, this kind of failure in IVC selection was major problem for the
current protein evolution. It is, therefore, still hard to determine whether the selection is
working as desired with this result.
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P No PCR product
oil wa
BirA: low affinity to KB Selected streptavidin mutants:
presumably high affinity to KB
if selection worked as desired
pre selection post selection
marker 1 2 3 4 5 6
-+ BirA
-+ streptavidin
2000 bp
850 bp
400 bp
P Streptaidin genes will
be amplified by PCR
Figure 8 Functional assays of selected streptavidin mutants from each round, via
model selection with BirA. Streptavidin genes and BirA genes were PCR amplified
with ketone biotin primers and mixed in a 1:10 ratio. IVC selection was performed
with these gene mixtures (as depicted in Figure 4). After pulling down with Ni-NTA
beads, the genes were again PCR amplified and analyzed on an agarose gel. After one
round of selection, enrichment of streptavidin mutants was observed. After the
second round of selection, the results were inconclusive due to contamination in the
PCR reaction.
We also analyzed sequences of several random clones from each round of selection,
but the sequence information would be significant only after we have a better assay to analyze
the binding affinity of each clone. Characterization of individual clones at each round of
selection can be performed by transferring current streptavidin gene fragments to bacterial
expression plasmid and expressing the streptavidin mutants in large scale. This, however,
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lane PCR was performed with Streptavidin
the gene mixture mutants from
1 before selection Round 0
2 before selection Round 1
3 before selection Round 2
4 after selection Round 0
5 after selection Round 1
6 after selection Round 2
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-+ (3
would not provide an entire view of each round of selection, and many clones should be
analyzed to get significant information.
We also noticed a problem with library design. The library used for these three rounds
of selection has a theoretical diversity of 10 9, which is the same number of compartments we
can practically generate. Assuming perfectly even distribution of genes to compartments (one
gene per droplet), we will only have a single copy of each streptavidin mutant gene.
Practically, some fraction of the library is always lost while we perform the entire process of
one round of selection. Since there is only a single copy of each mutant gene, it is highly
probable that we lose mutant genes with various binding properties at an early stage of the
selection. In order to circumvent any permanent loss of mutants, we should design a library
with lower diversity to ensure that we have several copies of each mutant.
Although the current library exhibits high sequence diversity, a significant portion will
produce inactive streptavidin mutants due to improper protein folding. Thus, the mutation rate
at the active site should be reduced to increase the number of properly folded and therefore
functional streptavidin mutants in the library. It should be also noted that a library with an
extremely low mutation rate will not give a novel mutant with the desired function, and thus
we need to optimize the mutation rate as well.
Design and construction of a streptavidin mutant library 2
A new streptavidin library for ketone biotin included seven positions (N23, L25, S27,
Y43, S45, V47 and D128; Figure 9) that are close to the upper ring of biotin. Theoretical
amino acid diversity of the library is same as before, 207 = ~109. We constructed the DNA
library by PCR overlap extension as described earlier. Instead of saturation mutagenesis at
each position, this time each residue was randomized so that 34% of the sequences in the
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Figure 9 Randomized positions in streptavidin mutant library 2. Residues close to the
upper ring of biotin and chosen for randomization were labeled.
Asn 23 Leu 25 Ser 27 Tyr 43 Ser 45 Val 47 sp 128
Rd 0-1 Ile Leu Thr Phe Ser Ser Asp
Rd 0-2 Asn Leu Pro Asn Ser Gly Glu
Rd 0-3 Ile Leu Ser Stop Ser Val Asp
Rd 0-4 Asn Met Ser Tyr Ser Val Asp
Table 2 Sequences of random clones from streptavidin mutant library 2
library would represent the wild type residue at a particular position. The new library 2 is
therefore more conservative than the previous library 1. Moreover, mutants in the library 2
have Hisio tags instead of His6 to ensure their tight binding to Ni-NTA beads. After
construction of the library, we checked the library by sequencing four clones at random (Table
2). All positions were mutated as expected from the design and we did not observe any
contamination by the wild type streptavidin gene.
Selection with the library (2)
The genes from the new library were prepared as before. For the first three rounds of
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selection, the in vitro transcription and translation mixture (IVTM) was incubated for 3 h.
Competition by incubation with 10 pM ketone biotin was performed for 25 min at round 1 and
for 30 min at round 2 and 3. We expected that more mutants in the library 2 will bind to ketone
biotin with higher affinities compared to those in the library 1, and thus competition will
provide finer discrimination of mutants with high affinities from those with moderate or low
affinities.
Functional assay: gel shift assays
Model selections with the BirA gene were used previously to test if there is a steady
increase in the binding affinity over the rounds of selection. As discussed above, however,
additional IVC selection for functional assay caused consistency problems. Thus, we
developed a new gel shift assay to estimate the affinities of newly evolved mutants. One molar
equivalent (eq) of biotinylated DNA fragments was incubated with WT streptavidin (biotin:
biotin binding site = 1: 4), and we observed shifted bands of streptavidin bound DNA on an
agarose gel (Figure 10, lane 1). For comparison, WT streptavidin was treated with 4 eq of free
biotin before it is incubated with biotinylated DNAs. In this case, all biotin binding sites
should be occupied by free biotin, but we observed a shifted band in addition to non-bound
DNA (Figure 10, lane 2). This kind of sub-stoichiometric binding of biotin to streptavidin has
been observed when relatively low excess (less than 10 eq) of biotin was used for streptavidin
binding 8 . When WT streptavidin was incubated with ketone biotin conjugated DNA
fragments, however, no shifted bands were observed due to weak interaction between WT
streptavidin and ketone biotin. We expected that, if the selection is working as desired (so that
streptavidin mutants, which bind ketone biotin tightly, are selected), we might see some
shifted ketone biotin-conjugated DNA fragments over the rounds of selection. However, we
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Lane Streptavidin (SA) DNA used for gel shift assay Pre-treatment of free lgand to streptavidin?
1 Wild-type Biotinylated DNA No
2 Wild-type Biotinylated DNA Yes, biotin
3 Wild-type Ketone biotin-conjugated DNA No
4 Wild-type Ketone biotin-conjugated DNA Yes, ketone biotin
5 Round 0 Ketone biotin-conjugated DNA No
6 Round 0 Ketone biotin-conjugated DNA Yes, ketone biotin
7 Round 1 Ketone biotin-conjugated DNA No
8 Round 1 Ketone biotin-conjugated DNA Yes, ketone biotin
9 Round 2 Ketone biotin-conjugated DNA No
10 Round 2 Ketone biotin-conjugated DNA Yes, ketone biotin
Wild type SA_
1 2 3 4
Rd0 Rdl Rd2
5 6 7 8 9 10
two DNA fragments + SA
one DNA fragment + SA
one DNA fragment
Figure 10 Functional assays on selected streptavidin (SA) mutants from each round
of selection, via gel shift. One molar equivalent (eq) of biotinylated DNAs was
incubated with wild type SA (biotin: biotin binding site = 1: 4, lane 1). In lane 2, wild
type SA was pre-treated with 4 eq of free biotin and then incubated with 1 eq of
biotinylated DNA. If the selected SA mutants bind to ketone biotin, we expect to see
shifted DNAs as in lane 1. Ketone biotin-conjugated DNAs (KB-DNA, 1 eq) were
incubated with wild type SA with (lane 4) or without (lane 3) prior treatment of free
ketone biotin (4 eq). In lanes 5, 7, and 9, KB-DNAs (0.1 nmole) were incubated with
selected SA mutants from each round without prior treatment of free ketone biotin. In
lanes 6, 8, and 10, KB-DNAs (0.1 nmole) were incubated with selected SA mutants
from each round with prior treatment of ketone biotin (0.4 nmole). No evidence of
binding to ketone biotin is seen in any of the lanes.
did not observe any shifted ketone biotin-conjugated DNA bands upon the incubation with the
streptavidin mutants, which were expressed in vitro from each round (Figure 10). The
sensitivity of ethidium bromide DNA detection might not be high enough to identify small
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amounts of shifted DNAs. Therefore, we also prepared DNA fragments with fluorophores on
one end and performed the same experiments in the hope that the fluorescence will offer a
higher sensitivity. Unfortunately, none of these attempts gave reliable data (data not shown).
Although we have successfully performed model IVC selection for streptavidin
evolution, two IVC selections to evolve a novel streptavidin that binds ketone biotin with
newly designed libraries were largely inconclusive. With still improving IVC technology and
tools to measure weak protein-small molecule interactions in hand, however, streptavidin
evolution against ketone biotin based on our developed assay may be realized in near future.
Conclusions
Here we have attempted to evolve novel streptavidin variants which show high
affinities toward ketone biotin using in vitro compartmentalization. In a model selection, the
100-fold enrichment of wild type streptavidin was obtained over S45A mutant, which binds
biotin 1000-fold weaker. Two different DNA libraries were designed and created. Selections
with these two libraries were performed using IVC. However, the protein evolution process
could not be confirmed due to the lack of a sensitive method to measure very weak bindings
between ketone biotin and streptavidin mutants selected during earlier rounds of selection. To
solve this problem of our selection, real time PCR could be used as an alternative approach.
Compared to our direct (measuring binding events) but rather qualitative and insensitive
functional assays, RT-PCR provides quantitative data on the varying levels of bound mutant
genes, therefore offering indirect but clear evidence regarding the selection process.
In our selection scheme, we only have two binding sites (at two ends of the gene) for a
streptavidin mutant in each droplet. Other directed evolution platforms usually include more
binding sites from five to a million. Multiple binding sites might be beneficial to avoid loss of
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weak binders from initial naive libraries9 , such as the library 1 used in earlier selections.
Due to its tetrameric property, directed evolution of streptavidin by other selection
methods was technically challenging. Cell surface displays inevitably include the anchor
protein, and the activity of proteins to be selected will be reduced by the presence of the
anchor protein. Monomeric streptavidin was reported to have a reversible binding to biotin (Kd
=10 7 M) because of its incomplete binding pocket1 9. Others recently showed that
homotetrameric streptavidin can be displayed on yeast cell surface by coexpression of the
native and anchored subunits of streptavidin 0 . Yeast surface display of streptavidin mutants
for affinity maturation toward ketone biotin would be worthy of investigation since the large
copy numbers of displayed proteins might capture weak binders by the avidity effect.
The IVC technology is in an early stage and should be improved further. Few
successful examples have been reported, and most are model selections, not providing any
information on novel proteins. However, once technical difficulties are resolved, IVC will be a
powerful tool for directed evolution of proteins, enabling high throughput investigation of
large libraries.
Experimental
Model selection of wild type and S45A streptavidin mutants (modified from Dr.
Chinnapen and Dr. Luo's protcol).
Preparation for making emulsions. 500 ptL of mineral oil mix was put in a Nunc CyroTube
vial with an 8x2 mm stir bar, and the vial was placed on ice to chill the oil mixture. Biotin-
conjugated genes were prepared as a 2.4 nM solution in 10 mM Tris-acetate pH 8. This will
give a final concentration of DNA in the IVTM of 200 pM. Two falcon tubes containing water
and absolute ethanol separately were prepared to rinse the homogeneizer.
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Making DNA/IVTM mixtures. In a 650 pL eppendorf tube, 22 pL of sterile water and 5 [tL
of 2.4 nM stock solution of singly biotinylated gene construct were mixed. For model
selections, DNA mixture was combined to achieve a final concentration of 200 pM in 60 pL.
To make 1:10, 1:100, and 1: 500 dilutions, serial dilutions of original stock solution were
made. The tube was then placed on ice. IVTM mixture was generated on ice by combining
11.5 gL of lysate, 9.6 pL of reaction mixture, 11.5 pL of amino acids, 0.98 pL of methionine, 5
pL of reconstitution buffer, and 0.9 gL of 1 mM biotin. Immediately prior to forming
emulsions, 33 pL of IVTM was added to the 27 pL of gene construct made as above. The
reaction mixture was remained on ice before homogenizing.
Forming Emulsions. The tube containing the mineral oil mixture was placed on ice and put
on the stirrer at 1,150 rpm. 50 pL of IVTM-DNA mixture were added to the stirring oil and
stirred further for 3 min. The oil became cloudy, and the tube was removed from the stirrer,
and the stir bar was also removed from the tube. The tip of the homogenizer was placed into
the tube and the mixture was homogenized at 11,000 rpm for 3 min. The homogenizer was
then removed, and the tube was capped and incubated at 30 'C for overnight. The
homogenizer was cleaned with one thorough wash with ethanol, followed by a thorough wash
with water. All traces of water in the final wash should be removed before next use.
Break Emulsions. 200 pL of quench buffer was added to emulsions and the mixture was
transferred to a clear 1.5 mL eppendorf tube. The mixture was then spun down at 15 'C with
13,000 rpm for 10 min. We usually saw a pellet of emulsions at the bottom of the tube, then an
aqueous layer of quench buffer, and a top layer of mineral oil. The layer of mineral oil was
removed. 1 mL of pure mineral oil (Sigma) was added to the tube and the pellet was re-
suspended by flicking with fingers. The tube was again spun down for 5 min at 15 'C with
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13,000 rpm. The top layer was removed again. Until no more pellet is observed and the
solution is clear, mineral oil was added and removed as above for three to four more times.
Any white interphase was removed. In order to remove residual mineral oil, 1 mL of hexane
was added. The mixture was resuspended and spun down for 1 min at 13,000 rpm. The hexane
layer was removed, and this hexane washing was repeated for two more times. Residual
hexane was evaporated off by air-drying for 10 min.
Binding to Ni-NTA beads. Seventy microliter of 50% slurry of Ni-NTA beads pre-
equilibrated in binding buffer was added to a 1.5 mL eppendorf tube. 180 pL of IVTM
reaction were added to the Ni-NTA beads, and the rest 20 pL of IVTM reaction were saved for
PCR amplification. The beads were than rotated at 4 'C for 2 h and washed with 1 mL of
binding buffer. The washing step was repeated once.
Competition of weak binders from beads. 200 pL of competition buffer (100 pM biotin in
Ni-NTA binding buffer) were added to the beads. The beads were then incubated at 37 'C on a
rotator for desired time (1-20 h). The beads were washed twice with 800 pL binding buffer. 50
pL double distilled H20 were added to the beads and the mixture were heated >90 'C for 15
min to denature streptavidin mutants.
DNA recovery by PCR from beads. 20 pL of the above slurry containing beads and
supernatant were added to a PCR reaction solution on ice containing 10 gL of I OX Pfu buffer,
4 pL of mixture of dNTPs (10 mM), 1 pL of 100 pM primer 1 (PIVB-9; 5'- TAT CCG GAT
ATA GTT CC), 1 pL of 100 pM primer 2 (LMB2-9; 5'- GTA AAA CGA CGG CCA GT), 2 pL
of Pfu-Turbo DNA polymerase, and 72 pL of sterile water. PCR was performed for the
following cycles: a) 94 'C 2 min, b) 94 'C 10 sec, c) 50 'C 30 sec, d) 72 'C 54 sec, e) repeat
b) to d) 19 times, f) 72 'C for 7 min, g) 4 'C forever. 2 pL of this PCR product was taken to
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the nested PCR reaction solution containing 10 ptL of 10X Pfu buffer, 4 ptL of mixture of
dNTPs (10 mM), 1 pL of 100 pM primer 1 (sacl-outer-R; 5'- GCT TTG TTA CCG GAT CCC
GG), 1 [tL of 100 pM primer 2 (PVX-rbs-ncol-F; 5'- TTA AGA AGG AGA TAT ACC ATG G),
2 pL of Pfu-Turbo DNA polymerase, and 72 pL of sterile water. PCR were cycled under the
same condition as above. PCR products were analyzed on an agarose gel.
Coupling of ketone biotin to 5'-amine modified oligonucleotides. The ketone biotin-
conjugated primers were synthesized as follows: 5 pL of 100 mM ketone biotin solution in dry
DMSO, 1 ptL of 500 mM N-hydroxysuccinimide in dry DMSO, and 1 pL of 500 mM N, N'-
dicyclohexylcarbodiimide were combined and incubated at room temperature for 12 h. One
microliter of this reaction was added to 5 pL of 200 tM 5'-amine modified oligonucleotides
(NH-LMB2-1: 5'- CAG GCG CCA TTC GCC ATT, NH-PIVB-1: 5'- GCG TTG ATG CAA
TTT CT) and 5 pL of 100 mM NaHCO 3 pH 8.3. The reaction was then incubated at room
temperature with rotation for 4 h. The crude reaction was run on reverse phase HPLC using a
gradient of 6 - 30% acetonitrile in 50 mM ammonium acetate over 30 min with a 1 mL/min
flow rate. Chromatogram was recorded at 260 nm. Intact oligonucleotides have retention times
of ~7 min (LMB2-1) and -9 min (PIVB-1), but after conjugation to ketone biotin, the
retention time should be increased to -10 min (ketone biotin conjugated LMB2-1) or - 1 min
(ketone biotin conjugated PIVB-1). Approximately 85% yield was observed for both coupling
reactions (Figure 11). The conjugated product was collected, lyophilized, and reconstituted in
water before use. MALDI-TOF analysis confirmed that the mass of conjugates match the
calculated number (Figures 3 and 4 in Appendix): ketone biotin conjugated PIVB-1= 5596.02
(observed), 5595.7 (calculated), ketone biotin conjugated LMB2-l = 5841.15 (observed),
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5839.9 (calculated).
LMB2-1 Ketone biotin conjugated LMB2-1
Ketone biotin conjugated PIVB1
PIVB1
7 8 9 10 11 1 13 min
LMB2-1: 5'-amine modified forward primer
PIVB1: 5-amine modified reverse primer
Figure 11 HPLC traces of ketone biotin modified oligonucleotides. The conjugation
reaction mixture was analyzed by C18 reverse-phase HPLC using a gradient of 6 -
30% acetonitrile in 50 mM ammonium acetate over 30 min with a 1 mL/min flow
rate. Chromatogram was recorded at 260 nm. Intact primers (LMB2-1: forward
primer for PCR, PIVB1: reverse primer for PCR) were run on HPLC for comparison.
The yield of conjugation was ~85% for both primers. The product peaks were
collected, lyophilized, and reconstituted in water before use.
Cloning of a partially-randomized streptavidin library by overlap extension PCR. The
first library was synthesized from a 1:1 mixture of the cis and trans libraries generated by Dr.
Chinnapen. The second library was synthesized from four fragments by overlap extension
PCR as described in Chapter 3. Fragment 1 was amplified from the pIVEX streptavidin
template using the primers LMB2-1 (5'- CAG GCG CCA TTC GCC ATT) and the
rv23_25_27 (5'- GTA CCA GGT GCC GGT GAT), using 30 reaction cycles as described
above. Fragment 2 was similarly amplified using the primers fw23_2527 (5'- ATC ACC
GGC ACC TGG TAC AAC CAG CTG GGA TCC ACC TTC ATC GTT AC, where A
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represents 7 0 % A and 10% each of the other bases, C represents 70% C and 10% each of the
other bases, and so forth; randomizes Asn 23, Leu 25, and Ser 27) and rv43_45_47 (5'- GGT
ACC GGT CAG AGC ACC). Fragment 3 was similarly amplified with the primers
fw43_45_47 (5'- GGT GCT CTG ACC GGT ACC TAC GAA TC GCT G0l GGT AAC
GCT GAA TC; randomizes Tyr 43, Ser 45, and Val 47) and rv128 (5'- GTG ACC AAC CAG
GGT GGA T). Fragment 4 was similarly amplified with the primers fw128 (5'- ATC CAC
CCT GGT TGG TCA CACAC CTT CAC CAA AGC; randomizes Asp 128) and PIVB1 (5'-
GCG TTG ATG CAA TTT CT). The final library was PCR amplified with the ketone biotin-
conjugated primers so that every member of the library has two ketone biotin at the ends.
Gel shift assays. DNA fragments (-300 bp) with biotin or ketone biotin at only one end were
prepared by PCR. In an eppendorf tube, 0.1 nmole of DNA fragments, 5.55 pL of 18 pM wild
type streptavidin, and 3.4 pL of lx PBS were added. Some wild type streptavidin was treated
with 0.4 nmole of free ligands (biotin or ketone biotin) before incubation with DNAs. In order
to analyze the binding of streptavidin mutants from each round, IVTM reactions with genes
from round 0, 1, and 2 were incubated at room temperature for 24 h to get large amount of
proteins. After breaking emulsions, addition of excess ketone biotin was omitted, and the
aqueous solution was purified with 70 pL of Ni-NTA agarose. The reaction mixture was then
incubated with 0.1 nmole of DNA fragments and analyzed immediately on an agarose gel.
References
I Green, N.M., Avidin. Adv Protein Chem 29, 85-133 (1975).
2 Wilchek, M. & Bayer, E.A., The avidin-biotin complex in bioanalytical applications.
141
Anal. Biochem. 171, 1-32 (1988).
3 Wilchek, M. & Bayer, E.A., Introduction to avidin-biotin technology. Methods
Enzymol. 184, 5-13 (1990).
4 Laitinen, O.H., Hytonen, V.P., Nordlund, H.R., & Kulomaa, M.S., Genetically
engineered avidins and streptavidins Cell. Mol. Life. Sci. 63, 2992-3017 (2006).
5 Reznik, G.O., Vajda, S., Sano, T., & Cantor, C.R., A streptavidin mutant with altered
ligand-binding specificity. Proc Natl Acad Sci USA 95, 13525-13530 (1998).
6 Dixon, R.W et al., Theoretical and Experimental Studies of Biotin Analogues That
Bind Almost as Tightly to Streptavidin as Biotin. J. Org. Chem. 67, 1827-1837 (2002).
7 Aslan, F.M., Yu, Y., Mohr, S.C., & Cantor, C.R., Engineered single-chain dimeric
streptavidins with an unexpected strong preference for biotin-4-fluorescein. Proc Natl
Acad Sci USA 102 (8507-8512) (2005).
8 Voss, S. & Skerra, A., Mutagenesis of a flexible loop in streptavidin leads to higher
affinity for the Strep-tag II peptide and improved performance in recombinant protein
purification. Protein Eng. 10, 975-982 (1997).
9 Leemhuis, H., Stein, V., Griffiths, A.D., & Hollfelder, F., New genotype-phenotype
linkages for directed evolution of functional proteins. Curr Opin. Struct. Biol. 15 (472-
478) (2005).
10 Sepp, A. & Choo, Y., Cell-free selection of zinc finger DNA-binding proteins using in
vitro compartmentalization. J. Mol. Biol. 354, 212-219 (2005).
11 Bertschinger, J., Grabulovski, D., & Neri, D., Selection of single domain binding
proteins by covalent DNA display. Protein Eng. Des. Sel. 20, 57-68 (2007).
12 Fen, C.X., Coomber, D.W, Lane, D.P., & Ghadessy, F.J., Directed Evolution of p53
142
Variants with Altered DNA-binding Specificities by In Vitro Compartmentalization. J.
Mol. Biol. 371, 1238-1248 (2007).
13 Chen, I., Howarth, M., Lin, W., & Ting, A.Y., Site-specific labeling of cell surface
proteins with biophysical probes using biotin ligase. Nat. Methods 2, 99-104 (2005).
14 Levy, M. & Ellington, A.D., Directed Evolution of Streptavidin Variants Using In Vitro
Compartmentalization. Chem Biol 15, 979-989 (2008).
"5 Hyre, D.E., Trong, I.L., Freitag, S., Stenkamp, R., & Stayton, P.S., Ser45 plays an
important role in managing both the equilibrium and transition state energetics of the
streptavidin-biotin system. Protein Sci. 9, 878-885 (2000).
16 Hughes, M.D., Nagel, D.A., Santos, A.F., Sutherland, A.J., & Hine, A.V., Removing
the redundancy from randomised gene libraries J. Mol. Biol. 331, 973-979 (2003).
17 Hyre, D.E. et al., Cooperative hydrogen bond interactions in the streptavidin biotin
system. Protein Sci. 15, 459-467 (2006).
18 Freitag, S., Trong, I.L., Klumb, L., Stayton, P.S., & Stenkamp, R., Structural studies of
the streptavidin binding loop. Protein Sci. 6, 1157-1166 (1997).
19 Wu, S.-C. & Wong, S.-L., Engineering Soluble Monomeric Streptavidin with
Reversible Biotin Binding Capability. J. Biol. Chem. 280, 23225-23231 (2005).
20 Furukawa, H., Tanino, T., Fukuda, H., & Kondo, A., Development of Novel Yeast Cell
Surface Display System for Homo-oligomeric Protein by Coexpression of Native and
Anchored Subunits. Biotechnol. Prog. 22, 994-997 (2006).
143
Chapter 5. An Engineered Aryl Azide Ligase for Site-Specific Mapping of
Protein-Protein Interactions via Photocrosslinking
The majority of this chapter has been published in: Baruah, H. Puthenveetil, S., Choi,
Y. A., Shah, S., and Ting, A. Y. An engineered aryl azide ligase for site-specific mapping of
protein-protein interactions through photocrosslinking. Angew Chem. Int. Ed. 47, 7018-7021
(2008). My specific contribution was as follows: I synthesized and characterized the aryl azide
probe used in this study.
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Introduction
Protein-protein interactions (PPI) govern a large number of cellular events'. Among
thousands of protein-protein interactions in a living organism, currently available techniques
have elucidated primarily the strong interactions with Kd < ~10-6 M2 . Understanding weak or
transient protein-protein interactions (Kd > 10 4 M) is also extremely important to fully
elucidate the details of biological pathways2,3. Non-invasive detection of these weak
interactions in cells has been a challenging task, due to the limitations of detection
technologies. For example, many protein-fragment complementation-based assays (PCAs),
including the yeast two-hybrid system4, split-Green Fluorescent Protein , split- f-lactamase ,
and split-luciferase7 '8 , and FRET (Fluorescence Resonance Energy Transfer9 ), are limited by
low sensitivity, narrow dynamic range, or the time for chromophore formation, which is longer
than the lifetime of weak protein-protein interactions'0 "1 . Recently, Regan and coworkers used
a split GFP system to detect weak interaction with a Kd of -1 mM However, it was
irreversible and did not allow any temporal control. Detection methods which require cell lysis,
such as immunoprecipitation, cannot detect weak or transient interactions as well because the
protein interaction must survive lysis, dilution, and several incubation and washing steps in
order to be detected.
Photoaffinity (PA) probes, containing photoactivatable moieties such as aryl azide and
benzophenone groups, have been successfully used to detect transient protein-protein
interactions, largely in vitro12 . The small size of PA probes introduces minimal steric bulk,
which reduces the rate of false negatives. Proteins labeled with PA probes usually retain the
ability to bind to their interaction partners, due to the small size of the PA probes (in contrast
to protein reporter based methodologies, which frequently give false negatives due to steric
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hindrance). Activated probes form covalent bonds with interacting protein partners in as little
as nanoseconds13 , enabling detection of transient interactions. Purification of the crosslinked
complexes and analysis by mass-spectrometry, Western blotting, or other techniques reveal the
identities of the interaction partners of the protein of interest. Moreover, only one protein
partner needs to be labeled (the other can be endogenous unmodified proteins) and thus false
negatives and positives are both minimized. Finally, photocrosslinking is compatible with all
cell types and all subcellular compartments, in contrast to yeast two-hybrid, for instance".
Despite the advantages offered by PA probes, their use in the live cell context, where
most relevant protein-protein interactions take place, has been limited by lack of suitable ways
to label cellular proteins with PA probes 5 . The best current method for photocrosslinker
introduction is unnatural amino acid mutagenesis1 6-22 . The non-position specific form of this
technique" 2,2 introduces high background, reduced signals, and potential interference with
protein functions. Position-specific unnatural amino acid mutagenesis1 6-20 is extremely
powerful, but its mammalian cell applications are often restricted by the prevalence of natural
amber codons23, low suppression efficiencies24 , and the generation of prematurely truncated
protein products, which can sometimes produce dominant negative effects. Methods that
enable the targeting of PA probes to specific proteins in the cellular context would greatly
expand our working tools for elucidating signal transduction pathways.
As a first step towards developing intracellular PA probe labeling methodologies as
proposed in Figure 1, the development and characterization of an aryl azide photoaffinity
probe ligase will be discussed in this chapter. This chapter will focus on how we rationally
designed the protein ligase that specifically introduces our aryl azide photoaffinity probe to a
substrate polypeptide. Dr. Hemanta Baruah found the first mutant of lipoic acid ligase (LpIA)
146
that takes an aryl azide probe and subsequently obtained a further modified ligase with a better
performance. Dr. Sujiet Puthenveetil performed photocrosslinking assays based on my
preliminary crosslinking experiments. Dr. Samit Shah provided mammalian expression
plasmids for this project. A significant portion of this chapter has been published on
Angewandte Chemie International Edition26.
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Aryl azide hV(j F FO ~ATP +()b
Figure 1 Scheme illustrating site-specific aryl azide ligation to LAP fusion protein,
followed by photocrosslinking to interacting protein. LAP is the LplA acceptor
peptide.
Results and discussion
Design, synthesis, and incorporation of aryl azide by wild type and mutants of LpIA
We first investigated the substrate selectivity of LpIA with several structural analogs
of lipoic acid. Lipoic acid is a carboxylic acid featuring a hydrophobic dithiolane ring. This
dithiolane ring is bigger than cyclopentane because of the size and electron repulsion of sulfur
atoms. Thus, we rationalized that LplA may accept a phenyl ring instead of the dithiolane ring
in its substrate pocket. Although lipoic acid has a stereogenic center, the active site of LplA
looks wide enough to tolerate the substrate diversity. Based on preliminary screening results
(data not shown), we synthesized a fluorinated aryl azide substrate 1 by simple coupling of 5-
aminopentanoic acid and N-hydroxysuccinimide ester of 4-azido-2, 3, 5, 6-tetrafluorobenzoic
acid (Figure 2). The design of the aryl azide analog as a substrate of LplA was rather
ambitious at this point since we installed an azide substitute on the phenyl group. The ability
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Figure 2 Synthetic scheme for aryl azide probe 1
of wild type LplA to utilize probe 1 as a substrate was subsequently tested. No product
conjugate was detected in the reaction with the probe. Further engineering of the active site
was necessary to make LplA to take this new substrate structure.
Engineering of Lp1A mutants to use aryl azide probe 1 (Dr. Baruah's work). Dr. Baruah
planned to mutate a series of amino acids that locate in the LplA active site to increase the
volume of binding pocket of the enzyme. The co-crystal structure of E. coli LplA with lipoic
acid has been reported27 , but structural information, providing more insights for lipoylation by
LplA, was obtained from lipoyl-AMP complex of LplA of Thermoplasma acidophilum (Ta)28
as we mentioned in Chapter 1. After examining the crystal structure, he chose nine amino acid
side chains (L18, D21, Y39, R72, Y73, T74, H81, L159, and H161) which are located within
7.5 A of the dithiolane ring of lipoic acid. He then generated individual alanine mutants of E.
coli LplA (L17, E20, W37, R70, S71, S72, H79, F147, and H149) to decrease side chain sizes
of these residues (Figure 3). HPLC analysis of incorporation reactions onto E2p by these LplA
mutants showed that W37A, E20A, and S71A mutants could accept probe 1 to a small degree.
Under identical reaction conditions, W37A was the best ligase for probe 1 among them.
Since W37 was the most important residue for recognizing probe 1, he produced more
W37 LplA mutants, and found that W37V LplA exhibited the higher probe 1 ligation activity
than W37A (Figure 4). This result indicates that the size of active site is not the only factor
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Trp 37
E col LplA
Figure 3 The active site of E. coli LpIA Lipoic acid is shown in yellow. With
single alanine mutation on Glu 20, Trp 37, or Ser 71 (shown in red), LplA could
ligate aryl azide 1 to E2p to a small degree, and W37A showed the highest ligation
efficiency. Further engineering on Trp 37 showed that W37V LplA exhibits the
higher ligation activity than any other mutants generated for aryl azide 1.
Aryl azide-LAP-HP1
conjugate
LAP-HP1
Aryl azide 1
-ATP negative control
Wild type LpIA
negative control
8 10 12 14 16 min
Figure 4 HPLC assay of W37V-catalyzed ligation of aryl azide 1 onto LAP fused
IHPI protein (LAP-HP1). When ATP is omitted or wild type LplA is used instead
of W37V, no product was observed. The two starred peaks were collected for
mass-spectrometry analysis. The aryl azide-LAP-HP1 conjugate has the calculated
mass for one molecule of aryl azide 1 plus one LAP-HP1 protein, minus water.
This figure was modified from the reference 26.
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that affects the catalytic efficiency of LplA. He determined a kcat of 0.31 ± 0.04 s-1 for the
ligation (the kcat of lipoic acid incorporation onto E2p by wild type LplA is 0.25 s-1)29, which is
greater than that of any other LplA-catalyzed ligation of unnatural probes developed so far.
However, Km was 80 pM or less (data not shown), which is considerably greater than the Km
of wild type LplA for lipoic acid (1.7 pM30 or 4.5 pM 27). Finally, he showed that aryl azide 1-
ligated LAP-HP1 protein has the calculated mass for one molecule of aryl azide 1 plus one
LAP-HP 1 protein, minus water. Both the aryl azide moiety and the protein substrate are intact
after the reaction by W37V LplA.
Specificity of aryl azide ligation by W37V LplA (Dr. Baruah's work). He then tested if the
W37V-catalyzed ligation of aryl azide shows the same specificity against the substrate protein
as the lipoylation. By virtue of the azide moiety, aryl azide-ligated proteins can be detected by
either Staudinger reaction31 or [3+2] cycloaddition 32 . After labeling the total lysate from HEK
cells expressing a LAP fusion to cyan fluorescent protein (LAP-CFP 29 ) with W37V LplA and
aryl azide 1, only LAP-CFP was subsequently modified with phosphine FLAG (via Staudinger
reaction, Figure 5A). In addition, aryl azide 1 could be modified with cyclooctyne-Cy3
conjugate 29 (via [3+2] cycloaddition) and therefore used for cell surface labeling in HeLa cells
expressing extracellular LAP fusion (Figure 5B). He also found that non-LAP proteins such as
FRB-AP, FKBP-AP, and BCCP-87 are not labeled with aryl azide 1 by performing ligation
reactions followed by mass measurement.
Application of aryl azide ligase for photocrosslinking proteins (Dr. Puthenveetil's work).
As a proof of principle experiment, we attempted to detect a known protein-protein interaction
(PPI) within a complex mixture. Model PPI complexes such as CFP dimer, HP 1 protein with
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Figure 5 Specificity of aryl azide ligation. (A) HEK cells expressing LAP-CFP
were lysed, and the lysate was labeled with aryl azide 1 in vitro. The ligated aryl
azide was detected by Staudinger reaction with phosphine FLAG. Blotting with
anti-FLAG antibody is shown to the left of the Coomassie-stained gel. Negative
controls are shown with an alanine mutation in LAP (lane 2), wild type LplA
instead of W37V (lane 4), and untransfected cells (lane 3). (B) HeLa cells
expressing LAP-CFP-TM were labeled with W37V LplA and aryl azide 1,
followed by cyclooctyne-Cy3 conjugate, to selectively derivatize the aryl azide.
Imaging shows pink Cy3 staining on the membranes of transfected CFP-positive
cells. No labeling was observed when aryl azide 1 was omitted (middle row) or
when LAP-CFP-TM was replaced by an alanine mutant (bottom row). This figure
was modified from the reference 26.
His6 tag and anti-His6 antibody, and a FRB-FKBP-rapamycin complex were tested for
demonstration of the use of the developed aryl azide ligase (W37V LplA). Photocrosslinking
of CFP dimer was highly inefficient and only possible using high concentration of CFP. The
interaction between His6 tag and anti-His6 antibody was too weak to give a strong signal of
crosslinking by western blot assays. FKBP is known to interact with FRB only in the presence
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Coomassie CFP fluorescence
Figure 6 Aryl azide-mediated photocrosslinking of FKBP and FRB in mammalian
cell lysate. The aryl azide 1 ligation was performed in vitro using recombinant
W37V LplA after lysis of HEK cells separately expressing FKBP-LAP and CFP-
FRB. The crosslinked heterodimer was detected by CFP imaging only in the
presence of rapamycin (lane 3, right gel). This figure was modified from the
reference 26.
of the small molecule rapamycin33 ,4 We finally chose this complex because 1) its interaction
is strong (FKBP-rapamycin + FRB <-> FKBP-rapamycinFRB: Kd = 12 nM, FRB-rapamycin +
FKBP*-+ FKBP-rapamycin-FRB: Kd = -100 fM) 33 and 2) the crystal structure of the complex
is reported, which will allow us to successfully locate the LAP sequence on the target protein.
We prepared FKBP-LAP (and Ala mutant of the lysine lipoylation site as a negative control)
and FRB-LAP constructs (and also Ala mutant), and native FKBP and FRB proteins without
any targeting sequence. FKBP-LAP and FRB-LAP proteins were separately incubated with
W37V LpIA, ATP, probe 1, and Mg2+, and the aryl azide incorporation was confirmed by the
HPLC and mass spectrometry readout (data not shown).
In order to optimize photocrosslinking reactions, various irradiation conditions have
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been applied. Major problem here was a background signal, probably caused by irradiation-
mediated random crosslinking of a highly stable FKBP/FRB complex. Even when the protein
was not labeled with probe 1, the band corresponding to heterodimer of FKBP and FRB was
seen under the mildest irradiation (data not shown). Another problem was very small
difference in molecular weights between homodimers and heterodimers of FKBP and FRB.
We could solve the problem by fusing either FKBP or FRB with other proteins such as BirA
(Here BirA was added to make a big difference in size. It does not play any role as an
enzyme.) or more simply CFP. Preliminary experiments with FRB-BirA and FKBP-LAP
looked promising (data not shown), and Dr. Puthenveetil further purified these proteins to get
clearer heterodimer bands. Finally, Dr. Puthenveetil performed the same experiments in HEK
cells separately expressing a FKBP-LAP and a CFP-FRB fusion. CFP fusion to FRB not only
made the signal more distinguishable on western blots, but also improved its expression in
mammalian cells. The lysates were combined and labeled with aryl azide 1, ATP, and W37V
LplA, prior to photocrosslinking with a 300-360 nm UV light for 4 min in the presence or
absence of rapamycin. After separation on SDS-PAGE gels, CFP-FRB proteins were detected
by in-gel CFP fluorescence (Figure 6). Only in the presence of rapamycin, with UV light
applied, and LAP tag intact, they observed a higher molecular weight band corresponding to
the covalent FKBP-FRB heterodimer.
Conclusions
We have demonstrated that E. coli LplA can be engineered to ligate unnatural aryl
azide to its peptide substrate LAP while not losing the high sequence-specificity of the enzyme.
LplA mutants could accept aryl azide with only single residue mutation. This feature of LplA
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is unique; although homologous to LplA, BirA, by contrast, did not show the same
malleability. It is probably due to the structure of lipoic acid, which does not have any
hydrogen bonding donor or acceptor and therefore only relies on the van der waals type
interaction for its binding to the enzyme. The ease of engineering as well as the hydrophobic
nature of the active site makes LplA a great enzyme for small molecule labeling onto target
proteins since most fluorophores and photoaffinity labels are hydrophobic. One drawback of
the methodology is that it is hard to pinpoint the exact interaction site due to the size of LAP.
In this case, unnatural amino acid incorporation methodology is superior to our method. Also,
if LAP is not located properly, the interaction partner could not be captured (false-negative)
even though it is interacting with the LAP-fusion protein.
It is also intuitively interesting to design a small molecule probe that can be used by
LplA. Investigating the small molecule specificity will give us additional insights on the
enzyme reaction, which might not be obtainable from the static crystal structure since one
small molecule should go through many conformational changes to be ligated. Compared to
biotin analogs, lipoic acid analogs can be relatively easily synthesized. Simple synthesis of
small molecule probes is always favorable, allowing others to apply the methodology For
example, ketone biotin is not widely used due to the difficulty of synthesis although the
methodology is extremely powerful.
Next goal of the project would be aryl azide labeling of proteins inside living cells.
Although it is not demonstrated with the aryl azide ligase yet, others in the lab have shown
intracellular proteins could be labeled with unnatural probes using co-expressed LplA.
Currently, we do not know if aryl azide 1 is membrane permeable. Membrane permeability
might be improved by esterification of the probe, increasing its hydrophobicity. If achieved, it
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will allow identifying many potential endogenous interaction partners of a protein of interest.
Experimental
General synthetic methods
Reagents were purchased from the described vendors and used without further
purification. Analytical thin layer chromatography was performed using 0.25 mm silica gel 60
F254 plates. Flash column chromatography was carried out using silica gel (ICN SiliTech 32-
63D). Mass spectra were recorded on an Applied Biosystems 200 QTRAP Mass Spectrometer
using electrospray ionization. High resolution Mass Spectra (HR-MS) were obtained at the
Mass Spectrometry Facility at MIT (Cambridge, MA). HPLC was performed on a Varian
Prostar Instrument equipped with an autosampler, using a reverse-phase 250 x 4.6 mm
Microsorb-MV 100 C18 column. Chromatograms were recorded at 210 nm unless otherwise
noted. 'H NMR and 9F NMR spectra were recorded on a Varian Mercury 300 MHz. Chemical
shifts are reported in delta (6) units, parts per million (ppm), and referenced to the residual
solvent peak. Coupling constants (J) are reported in hertz (Hz). The following abbreviations
for multiplets are used: s, singlet; dt, doublet of triplets; t, triplet; m, multiplet. Probes were
stored as 100 mM stock solutions at -20 'C in DMSO.
Synthesis of aryl azide analog 1
To a solution of 5-aminovaleric acid (Alfa Aesar, 12 mg, 100 tmole, 1.3 eq) in dry
DMSO (250 [tL), N-Succinimidyl 4-azido-2, 3, 5, 6-tetrafulorobenzoate (as ATFB, SE from
Invitrogen, 25 mg, 75 pmole, 1 eq) was added. The reaction was allowed to proceed overnight
at 45 'C in dark. The mixture was then acidified with 250 pL of 0.5 N hydrochloric acid and
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extracted with 400 pL of ethyl acetate three times. The combined extracts were evaporated in
vacuo and purified by silica chromatography using 2:1 hexane-ethyl acetate to yield 5-(4-
azido-2,3,5,6-tetrafluorobenzamido) pentanoic acid 1 as a white powder. Further
recrystallization in hexane-ethyl acetate provided 1 as a white needle crystal (3 mg, 12%).
TLC: Rf = 0.3 (1: 1 hexane-ethyl acetate) 1H-NMR (300MHz, (CD 3)2 SO): 6 12.03 (s, 1H),
8.89 (t, 1H, J = 5.4), 3.23 (q, 2H, J = 6.3), 2.22 (t, 2H, J = 7.2), 1.497 (m, 4H). 19F-NMR
(300MHz, (CD 3)2 SO): 6 -143.69 (m), 6 -151.95 (m). HR-MS m/z: (neg) [M-H]- calculated:
333.0616, observed: 333.0622.
Tests of various analog ligations to E2p with wild type LplA
To see if a structural analog is incorporated to E2p by wild type LplA, reactions were
assembled as follows: 1 pM LplA, 100 pM E2p, 500 pM probe 1, 1 mM ATP, and 4 mM
magnesium acetate in 25 mM sodium phosphate, pH 7.0. For the negative controls, ATP was
omitted from the reaction. LplA and E2p proteins were expressed and purified as previously
described. 29 Ligation reactions were incubated at 30 'C for overnight, and then quenched with
100 mM EDTA (final concentration). Reactions were analyzed by C18 reverse-phase HPLC
using a gradient of 30 - 45% acetonitrile in water with 0.1% trifluoroacetic acid over 20
minutes with a 1 mL/minute flow rate. E2p had a retention time of 12 min, but after
conjugation to a probe, the retention time should be increased -16 min.
Aryl azide ligation to FRB-LAP with W37V LpIA
Reactions were assembled as follows: 0.5 pM W37V LplA, 100 pM FRB-LAP, 250
iM aryl azide 1, 1 mM ATP, and 4 mM magnesium acetate in 25 mM sodium phosphate, pH
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7.0. For the negative controls, ATP was omitted from the reaction. Ligation reactions were
incubated at 30 0C for overnight, and then quenched with 100 mM EDTA (final concentration).
Reactions were analyzed by C18 reverse-phase HPLC using a gradient of 30 - 65%
acetonitrile in water with 0.1% trifluoroacetic acid over 20 minutes with a 1 mL/minute flow
rate. FRB-LAP had a retention time of 14 min, but after conjugation to a probe, the retention
time increased to 14.4 min.
Cloning of FRB-LAP and FKBP-LAP for bacterial expression
To clone FRB-LAP in pET-21b, we first amplified the FRB gene using the primers
FRBfw (5'- GGA TCC GTA TCC GTA CGA CGT AC) and LAPrv (5'- GAA TTC CGG TAC
TTC CAG AAC TAC TTT GTC GGT TTC GAT TTC AAC CAG TAC TTC GTC TTT GCC
CGA GCC CGA GGT C) to introduce an N-terminal BamHI site and a C-terminal 10-amino
acid linker (GSGSTSGSGK) followed by LAP (DEVLVEIETDKVVLEVPASADG) followed
by an EcoRI site. The PCR product was digested with BamHI and EcoRI enzymes and ligated
into similarly-digested pET-21b vector to obtain the FRB-LAP-pET-21b plasmid.
To clone FKBP-LAP in pET-21b, we first amplified the FRB gene using the primers
FKBPfw (5'- GGA TCC GGA ACA AAA ACT TAT TTC TGA AGA AG) and LAPrv to
introduce an N-terminal BamHI site and a C-terminal 10-amino acid linker (GSGSTSGSGK)
followed by LAP (DEVLVEIETDKVVLEVPASADG) followed by an EcoRI site. The PCR
product was digested with BamHI and EcoRI enzymes and ligated into similarly-digested
pET-21b vector to obtain the FKBP-LAP-pET-21b plasmid.
Bacterial expression and purification of FRB-LAP and FKBP-LAP in pET-21b
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The pET-21b plasmid containing the FRB-LAP (or FKBP-LAP) gene was introduced
into E. coli strain BL21 (DE3) by heat-shock transformation. The cells were cultured in LB
supplemented with ampicillin (100 pg/mL) at 37 'C until OD60 0 0.5. Protein expression was
induced by the addition of IPTG to a final concentration of 0.4 mM. After incubation at 30 'C
for 3 h, the cells were harvested by centrifugation. The cells were lysed by resuspension in
bacterial protein extraction reagent (B-PER, Pierce) supplemented with 0.5 mM PMSF,
protease inhibitor cocktail (Calbiochem), and DNase I (Roche). After incubation at room
temperature for 20 min, the lysate was cleared by centrifugation, and the supernatant was
loaded onto a Ni-NTA agarose column (Qiagen). Fractions containing FRB-LAP (or FKBP-
LAP) were consolidated and dialyzed against PBS pH 7.4 for overnight. The concentration of
protein was determined by BCA assay.
Photocrosslinking of FRB-LAP and FKBP-LAP in presence or absence of rapamycin
FRB-LAP (2 ptL of 10 pM stock, Cf=l pM) and FKBP-LAP (2 ptL of 10 pM stock,
Cf=l M) were added to a small eppendorf tube. To some reactions, 2 ptL of 100 pM
rapamycin was added (Cf=10 pM). Photocrosslinking was performed on 6 piL samples, placed
1.5 inches from a 800 W Hanovia UV lamp separated by Pyrex glass to filter out light <300
nm. After irradiation for 1, 3, 5 min on ice, we analyzed the samples by Western blotting using
anti-HA and anti-myc antibodies.
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Characterization of AP conjugated oligonucleotides :
HPLC and MALDI-TOF (Chapter 3)
Figure 1 HPLC analysis of the purified AP conjugated oligonucleotides (Chapter 3). AP conjugated
LMB3 (a forward primer for PCR; oligonucleotide sequence: GGA AGG GCG ATC GGT GCG) is
shown in red, and AP conjugated PIVB3 (a reverse primer for PCR; oligonucleotide sequence: GAG
CAC TGT CCG ACC GC) is shown in black. The purity of both samples are >90%.
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Voyager Spec #1=>SMS9(BP = 1104.1. G$)
V5112.ALDLMB3
[AP-LMB3]
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Figure 2 MALDI-TOF analysis of the purified AP conjugated oligonucleotide. AP conjugated LMB3
(a forward primer for PCR; oligonucleotide sequence: GGA AGG GCG ATC GGT GCG) is shown
here, and the observed mass (8010.06) matched with the calculated value (8005.7) within error range.
For some reason, we have failed to get mass peaks corresponding to AP conjugated PIVB3
(see Chapter 3 for further discussion)
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Characterization of ketone biotin conjugated oligonucleotides:
MALDI-TOF (Chapter 4)
Voyager Spec #1=>BC=>RSM2 0=z>NFO,7=>MCBP =1085.7, 38726
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Mass fmtx*
Figure 3 MALDI-TOF analysis of the purified ketone biotin conjugated oligonucleotide (PIVB-1).
PIVB-1 is a reverse primer for PCR (oligonucleotide sequence: 5'- GCG TTG ATG CAA TTT CT).
The observed mass (5596.02, the most left peak) matched with the calculated value (5595.7) within
error range. Multiple peaks are responsible for Na* or K increments, which are usually observed for
oligonucleotides.
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Figure 4 MALDI-TOF analysis of the purified ketone biotin conjugated oligonucleotide (LMB2-1).
LMB2-1 is a forward primer for PCR (oligonucleotide sequence: 5'- CAG GCG CCA TTC GCC ATT).
The observed mass (5841.15, the most left peak) matched with the calculated value (5839.9) within
error range. Multiple peaks are responsible for Na* or K* increments, which are usually observed for
oligonucleotides.
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Spectral characterization of aryl azide 1 (Chapter 5)
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Figure 5 'H-NMR spectra of aryl azide 1
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Figure 6 '9F-NMR spectra of aryl azide 1
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Sample ID: YC-AA-4 (-)C12H10F4N403, Theoretical Mass [M-H]: 333.0616
333 0622 YM-H-J
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334.0558
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Figure 7 HR-MS spectra of aryl azide 1
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